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Differential PAX5 Levels in B Cells Promote MCL Dispersal and Progression and 
Predict a Poor Prognosis in Advanced MCL Patients. 
 
Albert Eng Keong Teo, B.S. 
Advisory Professor: Nami McCarty, Ph.D. 
 
Abstract: Although PAX5 conditional silencing in mice models led to aggressive 
lymphoma formation, there has been a lack of understanding in the precise functions of 
PAX5 in human B cell cancers. PAX5 expression is used to diagnose different B cell 
lymphoma in the clinic including mantle cell lymphoma (MCL), which is one of the most 
aggressive B cell cancers. PAX5 levels in MCL patients were significantly repressed 
compared to normal B cells. Surprisingly, we found there were quantitative differences 
in PAX5 expression levels within MCL patient tissues, which prompted us to silence 
PAX5 in MCL cell lines to characterize PAX5 functions in MCL disease progression. 
PAX5 silencing in MCL cells (PAX5–) not only increased cell proliferation in vitro and in 
vivo but also contributed towards retention of quiescent PKH+ stem-like cells in 
xenograft bones. Decreased PAX5 signaling led to deregulation of the cell cycle and 
increased MCL survival pathways. PAX5– cells also exhibited increased dissemination 
and adhesion to bone marrow stromal cells.  Analyses of clinical MCL cases further 
revealed that lower PAX5 levels are correlated with MCL dispersal and poorer overall 
survival in patients. In addition, aggressive blastoid variant MCL demonstrated lower 
levels of PAX5 compared to non-blastoid types, indicating a decreased PAX5 
phenotype promotes MCL dispersal and progression. We also conducted a high 
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throughput screening (HTS) of 3800 compounds to discover compounds that 
selectively target the aggressive MCL. The data revealed important properties of 
PAX5– MCL cells, which are highly drug resistant compared to parental cells. Several 
novel compounds were discovered through the HTS, which can be new potential 
therapeutic options for aggressive MCL. Collectively, our data support PAX5 functions 
as a tumor suppressor-like protein in MCL, and that PAX5 expression can predict 
advanced MCL patient prognosis. 
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Chapter 1: GENERAL INTRODUCTION 
Mantle Cell Lymphoma 
 Mantle cell lymphoma (MCL) is categorized as a mature B cell lymphoma of the 
mantle zone, and was only defined as recently as the 1990s (Banks, Chan et al. 1992, 
Weisenburger and Armitage 1996). MCL accounts for approximately 6% of all Non-
Hodgkin’s Lymphomas (NHLs) in the Western world (Zhou, Wang et al. 2008, Sant, 
Allemani et al. 2010), are heterogeneous tumors that are highly refractory to standard 
radiation and chemotherapy, contributing to the worst survival rate among NHL patients 
(Vose 2012). Mantle cell lymphoma has a median diagnoses age of 67, and is typically 
twice as common in males compared to females (Smedby and Hjalgrim 2011). The 
median survival of MCL typically ranges from 3-5 years, though current therapy has led 
to an increase in overall survival (Martin, Chadburn et al. 2008, Herrmann, Hoster et al. 
2009). 
Pathology of Mantle Cell Lymphoma 
A major genomic abnormality in mantle cell lymphoma, which also distinguishes 
them from low-grade B cell lymphomas, is the t(11:14)(q13:q32) translocation, leading 
to increased cyclin D1 (CCND1) expression due to the juxtaposition of CCND1 with B-
cell IgG heavy chain transcriptional enhancers (Salaverria, Perez-Galan et al. 2006). 
This increase in CCND1 expression is linked to cell cycle deregulation (Fernandez, 
Hartmann et al. 2005), and tumor proliferation is the best predictor of survival in MCL 
(Rosenwald, Wright et al. 2003). Routine use of the Ki-67 cell proliferation index (% of 
Ki-67-positive lymphomas) in the clinic can serve a strong prognostic factor for overall 
survival (Tiemann, Schrader et al. 2005).   
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MCL cells show B cell associated antigens such as CD20, CD79 and the T cell 
associated antigens CD5. However, MCL cells do not express CD23, a critical receptor 
for B cell activation and growth (Jares, Colomer et al. 2007). MCL cells bear close 
topographic and phenotypic similarity to normal CD5-positive B cells, which also 
colonizes the mantle zone of lymphoid tissue and have the ability to recirculate (Dono, 
Cerruti et al. 2004).  
Mantle Cell Lymphoma Progression and Dissemination  
Mantle cell lymphoma is normally disseminated at presentation, with 20% - 30% 
of patients exhibiting a leukemic (high-grade bone marrow and peripheral blood) 
compartment (Perez-Galan, Dreyling et al. 2011). MCL has been reported to 
disseminate to the bone marrow, gastrointestinal tract (GIT), spleen, liver and central 
nervous system (Campo, Raffeld et al. 1999, Jares, Colomer et al. 2007). MCL 
xenografts in mice also depict a similar dissemination trend to the bone marrow, 
spleen, GIT and liver (Wang, Zhang et al. 2008, Chao, Tang et al. 2011, Klanova, 
Soukup et al. 2014).  
Mantle Cell Lymphoma Subtypes 
The blastoid variant type of MCL (MCL-BV) is a highly aggressive but a rare 
form of MCL and demonstrates a worse prognosis than the common forms of MCL 
(Argatoff, Connors et al. 1997, Bosch, Lopez-Guillermo et al. 1998, Bernard, Gressin et 
al. 2001). About 17% of diagnosed MCL cases are MCL-BV. MCL-BV has a median 
survival range of 12-24 months, significantly less than classical MCL (Bosch, López‐
Guillermo et al. 1998). MCL-BV is also marked with typical t(11:14)(q13:q32) 
translocation, loss of expression of cell cycle inhibitors (Pinyol, Hernandez et al. 1997) 
and genomic instability (Ott, Kalla et al. 1998). MCL-BV is often diagnosed at initial 
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presentation, often with leukemic involvement (Campo, Raffeld et al. 1999). It is rare for 
classical variants to histologically progress to MCL-BV (Argatoff, Connors et al. 1997). 
Such is the heterogeneity of MCL that there have been reports of an indolent 
form of the disease as well (Nodit, Bahler et al. 2003, Orchard, Garand et al. 2003, 
Espinet, Sole et al. 2005). 
Clinical Management of Mantle Cell Lymphoma  
The heterogeneity of mantle cell lymphoma biology poses a significant challenge 
to define standard therapies (Smith 2011), with frequent disease relapse and 
progressive resistance reported in the clinic (Dreyling 2011). Complete remission with 
conventional therapy is achieved in 20 – 80% of cases, but almost all will relapse 
(Jares, Colomer et al. 2007).  
This calls for an approach to understanding the disease biology to better 
overcome this problem in MCL. For example, the proteasome inhibitor bortezomib has 
been approved to be used in relapsed MCL patients after a failed first line therapy 
(Kane, Dagher et al. 2007). Bortezomib functions by disrupting the ubiquitin-
proteosome system (Molineaux 2012), thus causing endoplasmic reticulum stress 
(Pérez-Galán, Mora-Jensen et al. 2011). This occurs due to the accumulation of 
undegraded poly-ubiquitinated proteins, and apoptosis is induced in MCL through 
upregulation of Noxa (Perez-Galan, Roue et al. 2006). However, there are reported 
cases where second line therapy of bortezomib failed to clear the disease (Suh and 
Goy 2008), hinting to a population of MCL cells that are highly drug resistant. Current 
use of ibrutinib in the treatment of MCL (Wang, Rule et al. 2013) has improved the 
outlook of MCL prognosis significantly. However, recent reports (Young and Staudt 
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2014) suggest that tumor resistance may occur, signifying the need to understand the 
biology behind this drug resistant cells. 
Genomic Deregulation in Mantle Cell Lymphoma 
Reciprocal gene translocations involving the immunoglobulin genes are a 
common pathogenic event in lymphomas (Kuppers 2005). The t(11:14)(q13:q32) 
translocation observed in MCL leads to increase in CCND1 expression, cell cycle 
progression and promotes tumorigenesis (Kim and Diehl 2009). It is important to note 
however, that transgenic mice overexpressing CCND1 in B cells do not develop 
spontaneous lymphomas, revealing that overexpression of CCND1 by itself is not 
sufficient to induce MCL and indicating that other genetic pathways are necessary 
(Bodrug, Warner et al. 1994, Adams, Harris et al. 1999). Often times, gain of CCND1 
expression in MCL is synergized with the loss of a tumor suppressor (Bea, Salaverria 
et al. 2009). 
Indeed, MCL exhibit one of the highest degrees of genomic instability in B cell 
lymphomas (Jares, Colomer et al. 2007) leading to a highly heterogeneous disease. 
This instability causes loss of tumor suppressor expression or gain in oncogene 
activation (Bea, Ribas et al. 1999). The origin of this genomic instability is unknown; it 
is postulated that frequent re-initiation of entry into the S-phase due to CCND1 
overexpression leads to chromosomal abnormalities (Kim and Diehl 2009). 
Chromosomal aberrations of DNA damage checkpoint genes as well as genes related 
to microtubule dynamics was also discovered in MCL (Vater, Wagner et al. 2009), 
signifying that  loss of some genes might have a compounding effect as a whole due to 
genome wide effects.    
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The Paired Box 5 (PAX5) Protein 
Paired box 5 (Pax5) belongs to a family of nine PAX transcription factors  which 
play an important role in early mammalian development (Chi and Epstein 2002). Of the 
PAX proteins, it is the only one expressed within the hematopoietic system. Like other 
PAX family members, Pax5 has a conserved ‘paired’ domain, which functions as a 
bipartite DNA-binding region consisting of N- and C-terminal sub-domains (Czerny, 
Schaffner et al. 1993). This bipartite domain interacts with degenerate Pax5 
consensus-binding DNA sequences, and multiple sequence variants can increase the 
affinity of one half-site while decreasing affinity at the other half-site (Dorfler and 
Busslinger 1996). This enables Pax5 to affect a variety of genes, both in an activating 
or repressive manner (Delogu, Schebesta et al. 2006). This is achieved by recruitment 
of chromosomal remodeling and basal transcription factor complexes to the target loci 
(McManus, Ebert et al. 2011). 
PAX5 is a B Cell Transcription Factor 
Pax5 is a transcription factor that plays central roles in restricting the 
differentiation of lymphoid progenitors toward the B cell lineage (Hagman and Lukin 
2006). Pax5 is expressed throughout B cell development; from the pro-B cell stage, 
Pax5 is uniformly expressed until it is downregulation during plasma cell differentiation 
(Barberis, Widenhorn et al. 1990, Adams, Dorfler et al. 1992, Nutt, Heavey et al. 1999, 
Cobaleda, Schebesta et al. 2007) . Plasma cells and mature B cells differ significantly 
in their transcriptional program, and Pax5 expression is a key factor in the change.  
During this physiological down-regulation of Pax5, many Pax5-repressed genes are re-
expressed and B cell-specific genes are altered (Mikkola, Heavey et al. 2002, Delogu, 
Schebesta et al. 2006) 
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Precursor cells from Pax5 deficient (Pax5
-/-
) mice are blocked at the pro-B cell 
stage (Mikkola, Heavey et al. 2002), and these cells can differentiate into functional 
macrophages, granulocytes, dendritic cells, osteoclasts and natural killer cells in vivo 
(Mikkola, Heavey et al. 2002, Schaniel, Bruno et al. 2002). In vitro, Pax5
-/- 
pro-B cells 
differentiate into functional T cells in the presence of OP9 stromal cells expressing the 
Notch ligand Delta-like 1 (DL1) (Hoflinger, Kesavan et al. 2004). These highlights PAX5 
function as a master regulator for B cell identity, by fulfilling a dual role of activating B 
cell specific and concomitantly repressing lineage inappropriate genes (Revilla, Bilic et 
al. 2012).  
PAX5 in B Cell Lymphomas  
        Despite its established roles as a determinant in normal B cell lineage 
commitment, how PAX5 regulates development and progression of human B cell 
cancers is controversial. For example, in some lymphomas PAX5 has been implicated 
as an oncogene via gain-of-function mutations (Morrison, Jager et al. 1998). These 
mutations are often fusion mutations that retain DNA-binding specificity, that act in a 
dominant manner to repress wild type PAX5 function (Kawamata, Pennella et al. 2012, 
Fortschegger, Anderl et al. 2014).  
         In contrast, human B-progenitor acute lymphoblastic leukemias contain 
monoallelic mutations resulting in reduced PAX5 protein expression (Mullighan, Goorha 
et al. 2007) and a loss of wild type function. This was further corroborated when 
ablation of the Pax5 gene in mice B cells led to spontaneous B cell malignancies 
(Cobaleda, Jochum et al. 2007), which supports roles for PAX5 as a potential tumor 
suppressor. Indeed, recent evidence suggests that PAX5 loss is critical in gain of 
pluripotency in mature B cells (Hanna, Markoulaki et al. 2008), a trait similar to other 
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tumor suppressors (Hong, Takahashi et al. 2009). Mechanisms for PAX5 upstream 
regulation in B cell neoplasms are widely unknown, with PAX5 deregulation often due 
to genomic instability of cells (Mullighan, Goorha et al. 2007, Nebral, Denk et al. 2008, 
Familiades, Bousquet et al. 2009, Fortschegger, Anderl et al. 2014). Hence, exact roles 
for PAX5 in human lymphoma initiation and progression remain enigmatic.  
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Chapter 2: MATERIALS AND METHODOLOGY 
Cell lines and culture conditions 
The human mantle cell lymphoma cell lines SP53 and Jeko; human Burkitt’s 
lymphoma cell line Raji; human pre B-cell acute lymphocytic leukemia cell line Reh; 
human acute T-cell leukemia cell line Jurkat and human embryonic kidney cell line 
293FT were obtained from the American Type Culture Collection (Manassas, VA). HS5 
bone marrow stromal cells (BMSCs) was a kind gift from Dr. B. Torok-Storb (Fred 
Hutchinson Cancer Research Center, Seattle, WA). Cells were maintained under 
standard conditions (5% CO2, 37°C) and cultured in complete RPMI1640 medium 
(Cellgro, Manassas VA) supplemented with 10% FBS, 2mM L-glutamine, 100≤µg/mL 
streptomycin and 100 U.I. /mL penicillin.  
Human MCL samples 
Frozen blood or bone marrow specimens from MCL patients were obtained after 
informed consent, as approved by MDACC as well as by the University of Texas-Health 
Science Center Institutional Review Boards. Blood or bone marrow samples from non-
malignant donors were also obtained from MDACC. Mononuclear cells were isolated 
from all primary patient PBMC and normal PBMC using standard Ficoll (Pittsburgh, PA) 
gradient separation methods.    
RNA analysis 
Total RNA was extracted using a RNeasy Mini Kit (Qiagen, Valencia, CA) and 
cDNA synthesized using oligo dT-primers and SuperScript II Reverse Transcriptase 
(Invitrogen, Carlsbad, CA). cDNA was diluted 1:5 in DEPC-treated water prior to PCR 
amplification. Primers were designed using NCBI’s PrimerBLAST tool kit 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
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Quantitative real time-PCR 
qRT-PCR was performed using SYBR Green MasterMix Plus (Qiagen, Valencia, 
CA) on an ABI-7000 (Applied Biosystems, Foster City, CA) for 40 cycles. 1µL of diluted 
cDNA template was used in 20µL of reaction volume. β-actin or GAPDH expression 
served as the endogenous control for all qRT results.  
Semi-quantitative reverse transcriptase PCR 
Semi-quantitative RT-PCR was performed using the Qiagen HotStarTaq 
(Qiagen, Valencia, CA), and the products viewed on a 1.2% agarose gel. Terminal 
PCR was carried out on a BioRad thermocycler for 30 cycles, with varying annealing 
temperatures depending on each primer set. 2µL of diluted cDNA template was used in 
20µL of reaction volume. GAPDH served as the endogenous control for all RT results. 
Lentivirus generation and infection  
293FT cells were transfected with either shRNA specific for human PAX5 (Open 
Biosystem; Oligo ID: V2LHS-135477) or a lentivirus plasmid containing a scramble 
RNA (controls) or the ORF for human PAX5 (Open biosystem; Oligo ID: PLOHS-
100061597). Lentiviruses were then collected 48 hours post transfection followed by 
infection in the cells using polybrene (9 µg/mL). Media containing lentiviral particles 
were replaced with complete media 24 hours post infection and the cells were sorted at 
96 hours post infection for GFP expression. GFP+ cells were then selected using 
increasing amounts of puromycin (4 μg/mL starting) or blasticidin (2 μg/mL starting) to 
generate stable cell lines.    
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PKH staining and analysis 
B-cell lymphoma cell lines were stained with the membrane dye PKH26 (Sigma, 
St. Louis, MO) according to the manufacturer’s protocol. Briefly, up to 1 x 107 of 
lymphoma cells were washed in serum free media, then suspended in 1 mL Diluent C 
and the PKH26 dye were added at a ratio of 1:250. The cells were stained with the dye 
mixture for 5 minutes at room temperature. The staining process was quenched with 
addition of 1 volume of 100% serum for 1 minute. The cells were then washed twice 
with complete medium. PKH staining intensity was measured in multiple ways: using a 
LSR-II flow cytometer (BD Biosciences, San Jose, CA), an Infinite®M1000 (TECAN, 
Morrisville, NC) plate reader or using an Eclipse TE200-E (Nikon, Melville, NY) 
microscope.  
Fluorescence-activated cell sorting (FACS) and flow cytometry 
Cells were prepared using standard tissue culture protocols and suspended in 
2% FBS in PBS on ice before FACS. FACS was performed on a BD FACS Aria II 
system. Results were analyzed using the provided FACS Diva software. 
Apoptosis assay 
Cells were checked for apoptosis using the PE-Annexin V and 7-AAD staining kit 
(BD Pharmingen, San Jose, CA). Cells were stained and promptly run through a LSR-II 
flow cytometer (BD Biosciences, San Jose, CA) to determine the apoptotic index of cell 
populations.  
Cell cycle analysis 
Cells were harvested after cycling for at least 48 hours, and resuspened as 
single cell suspension. Cells were fixed in cold 70% ethanol, added drop wise to the 
pellet while vortexing. Cells were fixed on ice for 30 minutes, treated with ribonucleases 
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(RNAse A) and stained with 300µl propidium iodide (50 µg/ml). When analyzing the cell 
cycles, cell clumps and duplets were omitted, with only single cells analyzed.  
 CD45/GFP/PKH26 detection 
          Cells were stained with anti-CD45-APC (BD Pharmingen, San Jose, CA), or 
PKH26, and resuspended in FACS wash buffer prior to analysis.  
MethoCult™ colony assay 
Approximately 5 x 103 MCL cells were suspended in 1 mL of complete 
MethoCult™ medium and plated onto 35mm petri dishes.  Colonies were maintained at 
37°C with 5% CO2 and 95% humidity for 7 days. Colonies were counted and scored at 
day 7 and pictures taken using an Eclipse TE200-E microscope (Nikon, Melville, NY). 
Only colonies consisting of 50 or more cells were considered for analysis.  
In vitro adhesion assay 
24-well variant 
HS5 human BMSCs were seeded at a density of 5 x 104 cells/well in a 24-well 
plate and allowed to form a monolayer over 48-72 hours. MCL cell lines were stained 
with the membrane dye PKH26 (Sigma, St. Louis MO) according to the manufacturer’s 
protocol. Cells (5 x 105) suspended in 200µL of complete medium were then plated 
onto the pre-established monolayer of HS5 cells and allowed to adhere for 1 hour at 
37°C. After washing with 1 x PBS twice, PKH26 dye intensity was measured using an 
Infinite®M1000 (TECAN, Morrisville NC) fluorescent plate reader. Wells containing just 
MCL cells with no wash step served as 100% adhesion controls, while wells containing 
just the monolayer of HS5 cells served as 0% adhesion controls.   
96-well variant 
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Similar to the 24-well variant, but with HS5 human BMSCs seeded at a density 
of 1 x 104 cells/well in a 96-well plate and allowed to form a monolayer over 24-48 
hours. MCL cells (1 x 105) suspended in 100µL of complete medium.  
Immunoblotting   
Whole cell lysates were prepared using RIPA buffer (Boston BioProducts, 
Ashland, MA) containing phosphatase and protease inhibitors (Sigma, St. Louis, MO). 
Protein concentration was measured using a Bradford assay kit (Biorad, Hercules, CA) 
and 5 - 30 µg of whole cell lysate were run through either 10% - 15 % SDS gel. 
Proteins were transferred to methanol activated PVDF membranes. Membrane blots 
were blocked in either 5% non-fat milk or 5% animal-free blocker (Vector Labs, 
Burlingame, CA) and washed with 0.1% Tween-20 in TBS. Primary antibody 
incubations were done overnight at 4°C, or for two hours at room temperature with a 
dilution factor of 1:1000 – 1:4000. Secondary antibody incubations were done from 1 – 
2 hours, with a dilution factor of 1:2000 – 1:8000. Protein bands were visualized using a 
HyGLO ECL kit (Denville Scientific, South Plainfield, NJ).  
Immunohistochemistry 
 Tissues were fixed in 2% PFA (paraformaldehyde) in PBS, 30% sucrose before 
being snap frozen embedded in Optimal Cutting Temperature (OCT) compound prior to 
being sectioned. Sectioning was done by the IMM Histopathology Service Center 
(Houston, TX). Slides were stained with anti-CD45-PE (BD Pharmingen, San Jose, 
CA), for IHC bone marrow analysis. Nuclear staining was done using Draq5, with native 
GFP from PAX5– MCL being preserved and observed for as well. Slides were analyzed 
using a Leica TSC SP5 confocal microscope (Buffalo Grove, IL). 
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Motility assay 
Jeko and SP53 cells were stained with the membrane dye PKH26 as described 
above. 3 x 104 cells were suspended in 100 µL complete RPMI1640 were then plated 
onto empty 96-well plates. Cells were allowed to rest for 2-3 hours at 37°C before 
having their motions recorded using time lapse microscopy. Time lapse images were 
acquired with an Andor IXon3 885 EMCCD camera (Andor, Belfast, NIR) on an 
Olympus IX-81 (Olympus, Center Valley, PA) microscope fitted with a microscope 
enclosure (Precision Plastics, Rochester, NY) maintained at 37°C with 5% CO2. 
Images were analyzed using Amira® (FEI Visualization Sciences Group, Burlington, 
MA) as an analysis tool, with PKH26 labeled cells tracked over a 24 hour window.    
 NOD/SCID Xenograft assays and tumor evaluation  
Immunodeficient NOD/SCID mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME) and bred and maintained under barrier conditions at the University of 
Texas Health Science Center. For all in vivo studies, mice were maintained until they 
exhibited signs of distress that required euthanasia as designated by the protocol. 
PKH retention and engraftment assay  
Jeko and SP53 PAX5– MCL or control cells were stained with PKH26. PKH 
labeling was confirmed to be 100% by flow cytometry. The stained cells (1 x 106) were 
transplanted into NOD/SCID mice via intravenous injection (I.V) and mice were 
sacrificed 48 hours post injection. Cells from the spleen, vascular niche and 
osteoblastic niche were isolated and collected for analysis as reported. Briefly For our 
studies, the vascular and osteoblastic niches were combined to form the bone marrow 
sample. 
In vivo intravenous (engraftment) xenograft studies 
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Jeko and SP53 PAX5– MCL or control cells were injected into NOD/SCID mice 
via I.V. Mice injected with 1 and 5 x 106 cells were sacrificed 8 weeks post injection, 
with predicted organ dissemination sites collected for analysis. Mice used for survival 
analysis were injected with 2.5 and 5 x 106 cells and monitored every two days post 
injection for signs of morbidity and tumor burden. Human MCL cell engraftment in 
various xenograft tissues were analyzed using anti-CD45 staining and GFP by flow 
cytometry and immunohistochemistry.  
In vivo subcutaneous (dissemination) xenograft studies 
SP53 cells (3 x 106) were injected into the subcutaneous neck fold of NOD/SCID 
mice and SP53 cells (1.5 x 106) via I.V.. Xenografts were sacrificed 6 weeks post 
injection and PAX5 transcript levels determined from xenograft tumors. Subcutaneous 
tumor size was determined as previously described (Euhus, Hudd et al. 1986, Tomayko 
and Reynolds 1989) with tumor volume calculated by the modified ellipsoidal formula:    
Tumor volume = ½ (length x width2), where length is the longest longitudinal diameter 
and width is the greatest transverse diameter. 
Use of 18F-FDG was employed to detect dissemination of tumor cells to distant 
sites. Host mice with subcutaneous xenografts at 4 weeks were injected with 18F-FDG 
2.5 hours before being image, sacrificed and having select tissues measured using a γ 
counter. The results were expressed as a percentage of the injected dose per gram of 
tissue (%ID/g) relative to muscle controls which served as a baseline for glucose 
absorption.    
CellTiter-Blue® cytotoxicity assay 
Cytotoxicity was assessed with Fluorimetric cell viability assay using CellTiter-
Blue® (Promega, Madison, WI). Briefly, cells were incubated in 96-well plates for the 
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indicated times at 37 °C with determined doses of drugs. After the indicated incubation 
time, 20µl of CellTiter-Blue® reagents was added to suspended cells. Cells were 
further incubated for 2 – 4 hours at 37 °C. The fluorescent signal was measured at 
560Ex/590Em using a fluorescence plate reader equipped with SoftMax Pro software 
(Molecular Devices, Sunnyvale, CA), and the level of fluorescent resorufin was 
calculated. Dose-response curves were calculated based on the cell viability assay of 
cells treated with each chemotherapeutic drug. Cell viability was assessed based on 
the value of fluorescent signal of live cells with no drug treatments. Viability of drug 
treated cells was calculated based on a ratio of the fluorescent signal to that of the non-
treated control (DMSO). Blank media only readouts were used as baseline controls.  
High throughput screening (HTS)  
A high-throughput drug screening was carried out in collaboration with Dr. 
Clifford Stephen from the Center for Translational Cancer Research, Texas A&M 
University (Houston, TX). PAX5– MCL (Jeko and SP53) and scramble RNA control 
MCL cells were used to screen chemical compounds from the NCI Oncology/Custom 
Clinical, Prestwick and NCI libraries, a total of 3864 compounds. 
Conditions for the HTS 
Prior to the start of the screen, screening conditions (cell growth curve, positive 
inhibition control and final readout) were optimized to determine the best way to 
measure the inhibitory effects of the screened compounds. Cells at varying densities 
and cell numbers were measured over three or four days either by the MTT assays 
(CellTiterBlue™ Promega, Madison, WI) or by direct imaging of cells stained with 
nucleic acid (data not shown). Six compounds were selected as positive controls– 
paclitaxel, anisomysin, CCCP, etoposide, doxorubicin and doxetaxel. Three of the 
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compounds were analyzed further for consistency in inhibition across all cell lines. 
Finally, reproducibility assays were conducted with the one positive control 
(doxorubicin) in order to have a clear distinction between signals (positive controls, 
positive hits) and noise (negative controls, negative hits) during HTS screening. 
Procedure for the HTS 
The following screening protocol was used: 2000 cells were suspended in 
complete RPMI1640 medium (Cellgro, Manassas, VA) containing no 
penicillin/streptomycin and plated onto 384-well plates (Corning, Corning, NY) using a 
Multidrop® Combi Dispenser (Thermo Scientific, Waltham, MA). Compound addition to 
multiwell plates was performed using a Beckman Biomek FX robotic platform 
(Beckman Coulter, Brea, CA) equipped with a multichannel pod to ensure repeatability 
from experiment to experiment. Briefly, 50 nL of each compound was diluted into a well 
containing 50µL of cells, yielding a final 10 µM working concentration for each 
screened compound. Each assay was repeated twice, with CellTiterBlue® readouts 
taken using an Infinite®M1000 (TECAN, Morrisville, NC) plate reader. 
Compound analysis for the HTS 
Data gathered from our HTS of 3864 compounds was analyzed using the 
following protocol:  
Replicates (n=2) were averaged and the mean fluorescent intensity for 
proliferation for each compound tested was recorded. Any replicate with standard 
deviations (S.D.)> 20% (meaning a 40% difference in replicates) were omitted from 
further analysis. The cleaned data set was then analyzed in two different ways:  
Overall drug resistance: Compounds with <40% inhibition of our positive control 
(doxorubicin) was omitted. Differences of less than 5% between control and PAX5–  
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cells were also omitted. Thus, only compounds that inhibited cell proliferation by 40%, 
and with at least a 5% difference between control and PAX5– cells were recorded for 
drug resistance statistics.  
Significant differences between control and PAX5– cells: Compounds with 
differences between PAX5– and control cells that are less than the sum of the two S.D. 
for each cell type were omitted. For example: Compound A with a difference of 
proliferation of 20% was omitted as the S.D. for the two types of cells were 12% and 
18% each. This method of filtering results yielded a robust list of compounds that had 
proliferative differences that accounted for replication errors.  
Doxorubicin- and DMSO-treated cells served as positive and negative controls 
for cell inhibition respectively. Candidate compounds were chosen using the following 
criteria: (1) fluorescence level of at least 40% (40% inhibition) of corresponding 
doxorubicin control samples or (2) a ≥10%- 20% fluorescence level difference between 
PAX5 knockdown and control cells.  
Reagents  
Compounds and drugs 
The following chemical compounds were used for cell cytotoxicity studies: 
Bortezomib, doxorubicin and dexamethasone were acquired from the MD Anderson 
Cancer Center (MDACC) drug repository.  
Antibodies 
Anti-CD45-APC (BD Pharmingen, San Jose, CA), anti-CD45-PE (BD 
Pharmingen, San Jose, CA), anti-CD19-PE (BD Pharmingen, San Jose, CA), anti-
CD11a-PE (Biolegend, San Diego, CA; HI111), anti-CD18-APC (Biolegend, San Diego, 
CA; TS1/18) and anti-gp130-APC (R&D Systems, Minneapolis, MN) were used for 
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FACs analysis. The following antibodies were used for protein blots: anti-
phosphop44/42 MAPK (Cell Signaling, Danvers, MA), anti-phosphoAKT (Cell Signaling, 
Danvers, MA), anti-phosphop38 MAPK (Cell Signaling, Danvers, MA), anti-
phosphoSTAT3 (Cell Signaling, Danvers, MA), anti-phosphoSrc family (Cell Signaling, 
Danvers, MA), anti-PAX5 (AbCam, Cambridge, MA; 3852-1), anti- β-actin (Santa Cruz, 
Dallas, TX; C4), anti-STAT3 (Santa Cruz, Dallas, TX; K-15), anti-IL6 (Milipore, Billerica, 
MA), anti IRF4, anti CCND1 (Santa Cruz, Dallas, TX), anti p21 (Milipore, Billerica, MA), 
anti p27 (Milipore, Billerica, MA), anti p53 (Santa Cruz, Dallas, TX), anti pmTOR (Cell 
Signaling, Danvers, MA) and anti mTOR (Milipore, Billerica, MA).  
HS5 conditioned medium 
HS5-conditioned media (HS5-CM) was generated by incubating a monolayer of 
HS5 cells with fresh complete RPMI1640 medium for 3 days. The aspirated conditioned 
medium was collected and centrifuged at 2000 rpm for 5 minutes to remove cellular 
debris, and stored at -80°C.  To obtain a working concentration of HS5-CM, collected 
HS5-CM was diluted 1:1 with complete RPMI1640 medium. Recombinant human IL6 
(R&D Systems, Minneapolis, MN) was diluted in complete RPMI1640 medium to yield a 
working concentration of 5ng – 50ng/µL.  
Statistical analysis 
Data reported are expressed as experimental mean ± standard deviations. 
Statistical significance of differences between control and experimental groups was 
evaluated by the Student t-test, where p < 0.05 was considered statistically significant. 
All experiments and assays were repeated at least twice and performed in duplicate or 
triplicate.  
  
19 
 
IC50 determination 
IC50 value (the concentration of a drug that is required for 50% inhibition in vitro) 
was used to indicate the quantitative measure of the different cell killing effect of drugs. 
The Hill-Slope logistic model is used to calculate IC50 using CompuSyn software 
(ComboSyn, NJ, USA). 
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Chapter 3: LOSS OF PAX5 IN MCL CONTRIBUTES TO AN INCREASE IN CELL 
PROLIFERATION 
INTRODUCTION 
The exact role of PAX5 in B cell lymphomagenesis is currently unknown. PAX5 
expression has been reported to be loss in 30% of B cell acute lymphoblastic leukemia 
(B-ALL) cancers, with loss of function reported in over expression mutants. PAX5 
deregulation in B cell neoplasm is attributed to genomic instability (Mullighan, Goorha 
et al. 2007). As mantle cell lymphoma (MCL) exhibit a high degree of genomic 
instability (Jares, Colomer et al. 2007), we sought to investigate if PAX5 expression is 
altered in MCL. Mantle cell lymphoma is a disease marked with increased tumor 
burden and cell proliferation. Lymphnode tissue sections of MCL patients often exhibit 
increased proliferation markers, such as Ki-67, and increased proliferation is often 
times a marker for overall survival in MCL (Rosenwald, Wright et al. 2003). Since PAX5 
has been reported to exhibit properties of a tumor suppressor gene (Cobaleda, Jochum 
et al. 2007), we decided to examine PAX5’s role in mantle cell lymphoma. As 
previously outlined, MCL cells display a high proliferative index and MCL disease is 
marked with progressive tumor burden. Here, we examined PAX5’s expression in the 
clinic, possible role in cellular proliferation and tumorigenesis in vitro and in vivo. 
RESULTS 
PAX5 is downregulated in MCL cell lines and CD19+ cells from MCL patients  
To investigate PAX5 expression in mantle cell lymphoma (MCL), we performed 
a preliminary screen comparing PAX5 mRNA expression levels found in normal B cells 
with that from three primary MCL patients as well as two MCL cell lines, SP53 and 
Jeko. Two other non-MCL B cell lymphoma cell lines, Raji and Reh were also analyzed 
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for PAX5 mRNA levels. Jurkat, a T cell lymphoma cell line, does not express PAX5 
mRNA and served as a negative control. PAX5 mRNA was significantly reduced in all 
(MCL and non-MCL) B cell cell lines (Figure 1A), as well as in 3 MCL primary patient 
samples (Figure 1B). Interestingly, Jeko, a cell line derived from blastoid MCL (Alinari, 
White et al. 2009), exhibited significantly less PAX5 than SP53, a classical MCL 
variant.     
To further expand on the clinical relevance of our findings, we determined PAX5 
levels in more MCL patients. PAX5 immunostaining is often used to identify B cells or B 
cell derived lymphomas in the clinic, however, no studies have quantitatively compared 
PAX5 levels in distinct cell populations. Moreover, most studies performed used whole 
tissue biopsy extracts which contain different immune and stromal cells, which make 
interpretation of these data difficult. We conducted comprehensive PAX5 level analyses 
on 39 different primary MCL samples, consisting of 31 peripheral blood and 8 bone 
marrow biopsies (Table 1). PAX5 expression from MCL samples were compared to 
peripheral blood or bone marrow from health donors. Analyses were performed in a 
blind manner without knowledge of the disease prognosis or sites of collection, which 
were only traced back after completion of the study. In all screens, only CD19+ cells 
were analyzed, which were isolated by positive selection.  
 Compared to normal bloods or normal bone marrows, PAX5 levels in CD19+ 
cells from MCL patient samples were highly reduced  (Figure 1C and D), indicating 
PAX5 play a role as a tumor suppressor-like protein. Further analysis found that PAX5 
expression within MCL patients could be subdivided further into different groups from 
the same data set (for example, within the peripheral blood data set) suggesting that 
there potentially exists a differential PAX5 expression gradient in B cell lymphomas.  
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Figure 1: PAX5 is Downregulated in Mantle Cell Lymphoma. qRT-PCR analysis of 
PAX5 transcript levels in (A) 2 MCL cell lines, SP53 and Jeko, and 2 non-MCL, B cell 
tumors, Raji and Reh and (B) 3 CD19+ MCL patient peripheral blood. (C) CD19+ B cells 
were isolated from MCL blood or apharesis samples (n=31) or normal blood patients 
(n=10) and (D) CD19+ cells were purified from bone marrows of normal persons (n=8) 
or MCL patients (n=8) and PAX5 mRNA levels determined via qRT-PCR. Each 
replicate was run in triplicate with values normalized to GAPDH. * p < 0.05 (vs. 
PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Table 1: PAX5 Analysis: List of 31 MCL Patient Samples. MCL patient samples 
(n=39) were evaluated for PAX5 levels. A total of 31 peripheral blood and 8 bone 
marrow samples were used. All cases were stage IV with extranodal diseases. All data 
were recorded and collected at the UT MD Anderson Cancer Center. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
number 
Morphologic 
variant
1
 
Extranodal 
involvement 
Age  
(yr) 
Treatment 
status
2
 
1
Lymphoma staging verified by MD Anderson pathologist 
2
Treatment status of patients upon sample collection 
3
Cells were isolated from either fresh or previously frozen peripheral blood (PB) and bone marrow (BM) 
Unk. (Unknown status), PB (Peripheral Blood), BM (Bone marrow) 
Tissue 
collection
3
 
Sex 
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This highlights (Figure 1A and B), and the possible role differential PAX5 expression 
have in MCL progression. 
Generating a relevant model 
Our clinical data suggests that further downregulation of PAX5 could potentially 
contribute to MCL malignancy. To determine the role of PAX5 function in lymphoma, 
we used two cell line models stably knock down for PAX5: PAX5– Jeko and PAX5– 
SP53 MCL cells. Our expression vector contained turbo-GFP and an antibiotic 
resistance cassette, which could be used to select for GFP+ cells (Figure 2). Lentiviral 
transduction of PAX5shRNA (PAX5– ) efficiently silenced PAX5 expression in GFP+ 
SP53 and Jeko cells (Figure 3), while PAX5ORF (PAX5ORF) lentiviral infection 
generated cells overexpressing PAX5 (Figure 4).   
Next, we analyzed expression of select genes that are known to be regulated by 
murine Pax5 using qRT-PCR. Approximately 110 genes are normally repressed by 
Pax5 in murine B cells (Delogu, Schebesta et al. 2006, Pridans, Holmes et al. 2008). 
Among those genes, about 20 are not expressed in humans. We selected 13 genes 
from the list which had been previously reported to be involved in either cancer 
development or hematopoietic stem cell (HSC) biology (Table 2). Among these 13 
Pax5 repressed genes, 10 genes were significantly upregulated in PAX5– SP53 cells 
(Figure 5A), and 7 out of 13 Pax5 repressed genes were significantly upregulated in 
PAX5– Jeko cells (Figure 5A). These data suggest that PAX5 control a similar gene 
repertoire both in human and mouse cells which could contribute to uncontrolled MCL 
cell proliferation and ‘stem-like’ maintenance. 
Additionally, CD47 has been reported to be repressed by PAX5 (Delogu, 
Schebesta et al. 2006, Pridans, Holmes et al. 2008). CD47 acts as a “do not eat signal” 
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Figure 2: Lentiviral Mediated Knockdown of PAX5 in MCL Cell Lines. PAX5 
knockdown and ORF cassettes were transduced into SP53 and Jeko MCL cell lines. 
Expression vectors contained antibiotic cassettes for either puromycin or blasticidin. 
(Left) Jeko cells 2 days after transduction, before antibiotic selection. (Right) Jeko cells 
10 days post antibiotic selection.  
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Figure 3: PAX5 Expression is Reduced in PAX5–  MCL Cells. PAX5– MCL cells have 
decreased PAX5 mRNA (top) and protein (bottom) levels. Numbers above the 
immunoblots show densitometric values normalized to β-actin protein, with the average 
values from 2 immunoblots. * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. 
PAX5control; Student’s t-test).    
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Figure 4: PAX5 is overexpressed in PAX5ORF MCL cells. PAX5ORF cells have 
increased PAX5 expression. qPCR analyses (top) and immunoblots analyses of PAX5 
in SP53 and Jeko cells expressing PAX5ORF. Each value represents the mean ± S.D 
(n=3). * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s 
t-test).    
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Table 2: List of Selected Genes Repressed By Murine Pax5. List of selected genes 
that were previously reported to be repressed by murine Pax5. These genes are also 
involved in HSC biology or tumorigenesis. 
   
Gene 
Implications in HSC 
maintenance, distribution and 
differentiation 
Implications in tumorigenesis 
LMO2 Yamada Y et al (1998)1 Nam CH et al (2006)2 
CST7 Halfon S et al (1998)3 
 
FXYD5 
 
Nam JS et al  (2007)4 
CCR2 
Si Y et al (2010)5 
Kim J et al (2014)6 
Zhang J et al  (2010)7 
FLT3 
Gilliland DG et al (2002)8 
Kikushige Y et al (2008)9 
Kiyoi H et al (2002)10 
Gilliland DG et al  (2002)8 
VAV3 Vigorito E et al (2005)11 
Colomba A et al (2008)12 
Chang KH et al (2012)13 
SATB1 
Will B et al (2013)14 
Satoh Y et al (2013)15 
Chu SH et al (2013)16 
TTC3 Liu XL (2007)17 
 
LILRB4 Cella M et al (1997)18 Dobrowolska H et al (2013)19 
CCL3 Cook DN (1996)20 
Vallet S et al (2011)21 
Baba T et al (2013)22 
Notch1 Maillard I (2014)23 Grabher C et al  (2006)
24 
PARP1 Li X et al (2014)25 Curtin NJ (2005)26 
IFITM 
 
Andreu P et al (2006)27 
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in some cancer cells, which enables escape from immune surveillance (Chao, 
Weissman et al. 2012), and has been found to regulate metastasis and dissemination 
in both multiple myeloma and NHL (Kikuchi, Uno et al. 2005, Chao, Alizadeh et al. 
2010). PAX5– Jeko MCL cells exhibited increase of CD47 mRNA expression (Figure 
5B). 
In B cell lymphompoiesis, Pax5 expression is lost when B cells mature into 
plasma cells (Cobaleda, Schebesta et al. 2007). Knockdown of Pax5 have previously 
been reported to cause mature B cells to revert to a more plasmacytic like state (Nera, 
Kohonen et al. 2006), with increase in plasma cell transcription factors and proteins. 
PAX5– MCL cells upregulated transcription factors that determine plasmacytic 
differentiation, such as interferon regulatory factor 4 (IRF4) and PR domain zinc finger 
protein 1 (BLIMP1) by qRT-PCR and by immunoblottings (Figure 6). It is interesting to 
note that both our qRT-PCR and protein blots for PAX5– Jeko cells yielded no 
significance increase in IRF4 expression, an observation consistent with Jeko.BR 
(bortezomib resistant) sub clones which exhibit plasmacytic characteristics (Pérez-
Galán, Mora-Jensen et al. 2011). We also tested PAX5– MCL cells for XBP-1 splicing, 
as the spliced form of XBP-1 is the isoform that is translated and plays a role in the 
unfolded protein response during plasma cell development (Shapiro-Shelef and 
Calame 2004). However, there were no spliced variant present (Figure 7A). This is 
again consistent with what was previously reported, where plasmacytic MCL cell lines 
did not lead to increased XBP-1 spliced isoforms (Pérez-Galán, Mora-Jensen et al. 
2011), suggesting that XBP-1 splicing is a late event of plasmacytic differentiation. In 
addition, we found the plasma cell marker, CD138, was increased at steady state levels  
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Figure 5: PAX5– MCL Cells Have an Upregulation of Pax5 Repressed Genes. (A) 
PAX5– cells demonstrate increased expression of PAX5 repressed genes. Gene 
expression was analyzed by qRT-PCR. Out of the 13 genes that are repressed by 
murine Pax5, 10 genes (SP53) and 8 genes (Jeko) were  upregulated  in PAX5– cells. 
Each value represents the mean ± S.D (n=3). Gene expression was normalized to 
ACTB mRNA levels. (B) RT-PCR analysis of CD47 in Jeko control or PAX5– cells. 
GAPDH served as loading controls. * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 
0.005 (vs. PAX5control; Student’s t-test).    
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Figure 6: PAX5– MCL Cells Have an Upregulation of IRF4 and BLIMP1. (Top) 
PAX5– cells have increased levels of BLIMP1 and IRF4 expressions compared to 
controls. Gene expression was analyzed using qRT-PCR, with results normalized to 
GAPDH. (Bottom) Immunoblot analyses of PAX5– MCL cells for IRF4 with β-actin 
serving as the loading control. * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 
(vs. PAX5control; Student’s t-test).    
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in SP53 PAX5– SP53 cells (Figure 7B) and in both PAX5– cells upon bortezomib 
activation (Figure 7B).  
PAX5– MCL cells displayed increased tumorigenic traits   
Since PAX5 conditional knock out murine B cells increased lineage plasticity by 
developing T cells upon adoptive transfer into RAG2-/- mice (Cobaleda, Jochum et al. 
2007), we analyzed colony-forming abilities of PAX5– MCL cells using 
phytohemagglutinin leukocyte (PHA-LCM) conditioned medium, which was used to 
measure stem-like properties in myeloma (Matsui, Huff et al. 2004). PAX5 silencing 
significantly increased frequency of colony-forming units of MCL cells compared to 
control cells (Figure 8), as well as displaying a larger colony overall (Figure 8). 
We further analyzed the effect of PAX5 gene silencing on engrafted stem-like 
cells using PKH dye as described previously (Chen, Orlowski et al. 2014).  PKH26 is a 
fluorescent lipophilic compound that labels the cell membrane, and its fluorescent 
intensity decreases with each cell division (Parish 1999). Since stem cells are largely 
quiescent, PKH26 has been used to monitor engraftment of HSC and lymphoid cells 
(Lanzkron, Collector et al. 1999, Lanzkron, Collector et al. 1999) or to identify cancer 
stem cells (Mangioni, Fruscio et al. 2012, Xue, Yan et al. 2012). 
We allowed 100% PKH26 labelled GFP+ MCL cells to undergo cell cycling in 
vivo for 48 hours and calculated PKH26+ recovery rates in different tissues using FACS 
analyses. Similar to the HSC reported previously (Lanzkron, Collector et al. 1999), the 
highest amounts of PKH+ cells were recovered after 48 hours of in vivo cell cycling 
(data not shown). Therefore, all the following analyses were performed at 48 hours 
post transplantation. Human cell engraftment was analyzed based on the number of 
CD45+ and PKH26+ in each tissue using FACS.  
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Figure 7: PAX5– MCL Cells Have an Upregulation of CD138 but Do Not Undergo 
Plasmacytic Differentiation. (A) PAX5– cells do not have spliced XBP-1, an important 
event for plasmacytic differentiation. Two different XBP-1 primer sets were used to 
determine the splice variant (shorter isoform). Arrows indicate where splice variant 
band will show. (B) Marker for plasmacytic differentiation, CD138 expression is 
increased in PAX5– cells upon bortezomib treatment. FACS analyses were performed 
at 72 hours post bortezomib treatment (n=2). * p < 0.05 (vs. PAX5control; Student’s t-
test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Figure 8: PAX5– Cells Demonstrate Increased Colony Formation. PAX5–  cells 
(5000) were seeded in PHA-LCM and colonies were scored at day 7. Only colonies 
containing > 50 cells were considered as a positive score. Inset: PAX5– cells also 
formed larger colonies in PHA-LCM as visualized using a 20 x objective light 
microscope. Each value represents the mean counted colonies ± S.D (n=3). * p < 0.05 
(vs. PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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MCL cell engraftment based on GFP+ was not different between two cell types 
after short incubation of 48 hours in vivo. Surprisingly, however, recovery rates of PKH+ 
cells population were significantly higher in PAX5– xenografts compared to control 
xenografts (Figure 9, Table 3). After 48 hour in vivo cycling, 21.5% of PKH+ cells were 
recovered from the bone marrows of PAX5– SP53 xenograft mice, compared to just 
18.2% of PKH+ cells recovered from controls, resulting in an 18% increase in 
engraftment. We also found a similar trend in PAX5– Jeko xenografts, which had 14% 
PKH+ cell recovery vs 10.4% in controls, which is a 35% increase in engraftment 
(Table 3). PKH+ cell engraftment of PAX5– cells was also higher in the spleens, 
however, the levels of increase was less than bone marrows (6.5% in SP53 and 25% in 
Jeko). This hinted at PAX5– cells to have a more quiescent like trait, or increase 
membrane retention. IHC analysis of xenograft mice bones and spleens confirmed the 
FACS findings (Figure 10 and 11), with arrow pointing at CD45+ cells. PKH intensity 
varies within cells, with PAX5– cells exhibiting a higher dye-retention. 
PAX5 affects cellular proliferation  
We then compared the PAX5– MCL in vitro cell proliferation to control cells. 
Proliferation was significantly increased in PAX5– MCL and this trend was repeated in 
PAX5– Raji and PAX5– Reh cells, non-MCL lines (Figure 12). On the other hand, PAX5 
overexpression led to severely reduced cellular proliferation (Figure 12) and increased 
apoptosis in MCL cells (Figure 13) as well as in Raji and Reh (Figure 14). Jeko PAX5– 
cells were compared to PAX5ORF cells and cell proliferation determined after 6 days in 
culture.  
We then examined cell cycle distribution of the PAX5– MCL cells. On average, 
PAX5– MCL cells had 50-60% more cells in the S-phase compared to control cells,  
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Figure 9: PAX5– Cells Demonstrate Greater PKH26+ Cell Retention in Xenograft 
Mice. (A) PAX5– cells have increased PKH26+ cell retention in xenograft mice.  
PKH26+ GFP+ PAX5– cells (1x106) cells transferred to NOD/SCID mice. Mice were 
sacrificed after 48 hours and cells from bone marrows and spleens were collected. 
FACS analyses are representative of 4 samples. * p < 0.05 (vs. PAX5control; Student’s t-
test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Table 3: (%) PKH26+ Cell Populations Quantitated from CD45+ Cells. PKH26+ cell 
populations quantitated from CD45+ cells via flow cytrometry. Cells were isolated from 
host spleen and bone marrow. 
  
SP53.PAX5
control
 
# of cells injected 
via tail vein # of mouse 
Tissue Examined % PKH26+ cells 
recovered 
Spleen / Bone marrow  
17.70 / 17.30 
17.00 / 18.50 
1 
1 
1 
1 
17.60 / 17.95 
18.00 / 19.10 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
SP53.PAX5
-
 
# of cells injected 
via tail vein # of mouse 
Tissue Examined % PKH26+ cells 
recovered 
Spleen / Bone marrow  
19.10 / 24.70 
18.30 / 21.15 
1 
1 
1 
1 
17.90 / 21.35 
19.60 / 18.95 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
Jeko. PAX5
control
 
# of cells injected 
via tail vein # of mouse 
Tissue Examined % PKH26+ cells 
recovered 
Spleen / Bone marrow  
11.20 /   8.95 
10.70 / 11.50 
1 
1 
1 
1 
14.70 /   9.50 
 9.70   / 11.85 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
Jeko.PAX5
-
 
# of cells injected 
via tail vein # of mouse 
Tissue Examined % PKH26+ cells 
recovered 
Spleen / Bone marrow  
13.70 / 13.00 
12.40 / 13.65 
1 
1 
1 
1 
14.10 / 13.95 
14.00 / 13.15 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
1 X 10
6
 
1 18.20 / 16.65 1 X 10
6
 
17.58 / 18.21 
18.73 / 21.53 
11.58 / 10.45 
14.48 / 14.08 
Average 
Average 
Average 
Average 
6.5% / 18.2% 
25% / 34.7% 
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Figure 10: PAX5– Cells Demonstrate Greater PKH26+ Cell Retention in Xenograft 
Mice Spleen. Representative spleen confocal images of GFP- and PKH-positive cells 
are shown. White arrow points to cells that are GFP positive with PKH26 staining. 
Scale bar, 25µm.  
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Figure 11: PAX5– Cells Demonstrate Greater PKH26+ Cell Retention in Xenograft 
Mice Bone Marrow. Representative spleen confocal images of GFP- and PKH-positive 
cells are shown. White arrow points to cells that are GFP positive with PKH26 staining. 
Scale bar, 75µm.  
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Figure 12: PAX5 Silencing in MCL Leads to Increased Cellular Proliferation. 
PAX5– cells were seeded at an initial 2000 cells and allowed to cycle for 7 days. Viable 
cells were counted using Tryphan Blue at days 0, 2, 4 and 7. Each value represents the 
mean ± S.D (n=3). * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. 
PAX5control; Student’s t-test).    
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Figure 13: PAX5 Overexpression Leads to Cell Death in MCL Cells.  Apoptotic 
evaluation of SP53 and Jeko cells expressing PAX5ORF using FACS analysis. Cells 
were cycled in culture for > 1 week before stained with Annexin V and 7AAD. Results 
are representative of two independent experiments. 
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Figure 14: PAX5 Overexpression Leads to Cell Death in non-MCL Cells.  Apoptotic 
evaluation of Raji and Reh cells expressing PAX5ORF using FACS analysis. Cells were 
cycled in culture for > 1 week before stained with Annexin V and 7AAD. Results are 
representative of two independent experiments. 
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while exhibiting less cells in the G0/G1 stage, 30-40% less cells (Figure 15). This 
points to a higher progression of the cell cycle, and corroborates our observations in 
cell proliferation (Figure 12). 
To investigate whether PAX5– cells could form a larger tumor (a measure for 
tumor burden), we transplanted 3 x 106 SP53 PAX5– and control cells into the 
subcutaneous neck fold of NOD/SCID mice. Tumors were measured at week 4 and 
PAX5– xenografts on average had tumors with larger volumes (Figure 16A). 
Interestingly, we found that PAX5– subcutaneous tumors to have a trend of increased 
glucose uptake (Figure 16B) when hosts were injected with 18F-FDG, though the data 
was not significant. However, an increased metabolic rate is tied to increased 
proliferation (Haberkorn, Strauss et al. 1991), suggesting that PAX5– cells causes an 
increased tumor burden in vivo. 
Since PAX5 silencing increased cellular proliferation in vitro and in vivo, we 
examined expression levels of selected genes that are involved in the cell cycle. 
Deregulation of cyclin-dependent kinases (CDKs) has been linked with increased 
cellular proliferation, as well as genomic and chromosomal instability which could lead 
to acquisition of genetic alterations that can contribute to tumor progression (Kastan 
and Bartek 2004, Massagué 2004, Malumbres and Barbacid 2005) . Compared to 
control MCL cells, PAX5– MCL cells demonstrated increased levels of CDK1, CDK2 
and CDK6 mRNA, as well as the corresponding cyclins at steady state level (Figure 
17). CDK1 is a well-studied mitotic CDK with cyclin A or B as its substrate, whereas 
CDK2 and CDK6 are interphase CDKs which requires cyclin A/E and cyclin D 
respectively (Malumbres and Barbacid 2005). CDK4 mRNA is increased in SP53 
PAX5– cells; however Jeko PAX5– cells had the same amount as control cells (Figure  
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Figure 15: PAX5 Knockdown Leads to an Increase of Cells in the S-Phase.  
Propidium iodide staining of cells exhibit a higher % population of cells in the S-phase 
of the cell cycle in PAX5–  cells. Cells were cultured for at least 48 hours before stained.  
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Figure 16: SP53 PAX5– Cells Form Larger Tumors in vivo.  (A) A total of 3 x 106 
PAX5– SP53 cells or control cells were injected into NOD/SCID mice (n=9) via 
subcutaneous injection and tumor volumes measured with a digital caliper after 4 
weeks. (B)
 18F-FDG counts of subcutaneous primary tumor and muscle tissue 
harvested from SP53 PAX5–or control xenografts. (%) ID / g of each target organ was 
normalized to a standardized control and CPM normalized to weight of each tissue, 
with tumors than normalized to muscle tissue for glucose baseline absorption. * p < 
0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).      
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Figure 17: PAX5– Cells Overexpress Cell Cycle Promoting Genes.  qPCR analysis 
of common cell cycle genes in PAX5– cells. Readouts were normalized to ACTB. All 
cells used in the experiments were selected for GFP+ and stable cell lines were 
generated via antibiotic selection. * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 
0.005 (vs. PAX5control; Student’s t-test).    
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18). We also observed an increase in E2F family member 4 and dimerization partner 
DP1 gene (TFDP1) expression in PAX5– MCL cells compared to controls (Figure 17). 
The E2F family of transcription factors and its binding partners play a critical role in cell 
cycle development from transition of the G1 to S phase, as complexes negatively 
regulate RB tumor suppressor pocket proteins retinoblastoma protein (Hagman and 
Lukin 2006), p107 and p130.  
TP53, RB and CDKN1A (p21) are tumor suppressors, with deregulation of these 
genes and proteins leading to the development of lymphomas (Chilosi, Doglioni et al. 
1996, Lee, Cam et al. 2002). We observed that SP53 cells which harbor wild-type p53 
(Ding, Whetstine et al. 2001, Drakos, Atsaves et al. 2009) express decreased levels of 
TP53, CDKN1A and CDKN1B upon PAX5 silencing by semi-quantitative RT-PCR 
(Figure 18A) and by immunoblots (Figure 18B). Jeko cells with TP53 deleted mutants 
(Drakos, Atsaves et al. 2009), exhibited lower levels of retinoblastoma protein (RB1) 
gene transcript as well as CDKN1A upon PAX5 silencing (Figure 18A), indicating 
PAX5 silencing affect tumor suppressor gene expression regardless of TP53 
mutational status. These collective effects lead to increased MCL cell proliferation. 
Serum starvation can be employed as a means to force systemic shock to select 
for tumorigenic like cell populations (Tavaluc, Hart et al. 2007), and we found PAX5– 
MCL cells thrived under serum starved conditions; PAX5– MCL cells had significantly 
increased cell survival in 2% or 5% serum conditions (Figure 19) indicating PAX5 
silencing promotes MCL cell proliferation not only in normal conditions (10%) but also 
under stressed cell culture conditions.   
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Figure 18: PAX5– Cells Express Decreased Levels of Cell Cycle Regulating 
Genes.  (A) Semi quantitative RT-PCR analysis of potential cell cycle inhibitors 
deregulated upon PAX5 silencing. SP53 is TP53 wild type and Jeko has TP53 mutant 
deletion. GAPDH serves as a loading control. (B) Immunoblot analyses of cell cycle 
inhibitors p53, p27 and p21 in PAX5– and control cells, with β-actin serving as the 
loading control. 
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Figure 19: PAX5– Cells Proliferate Faster Under Serum Starved Conditions.  (A) A 
total of 50,000 PAX5– cells were cultured in two different low serum conditions and 
allowed to cycle for 7 days. Viable cells were counted using Tryphan Blue at days 0, 1, 
4 and 7. Each value represents the mean ± S.D (n=3). * p < 0.05 (vs. PAX5control; 
Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Since PAX5– MCL cells demonstrated a better survival rate under this stressed 
condition, we then analyzed several IL-6 related genes upon serum restriction (Zhang, 
Yang et al. 2012). Compared to control cells, PAX5– cells showed higher proliferation 
rate in lower serum conditions (Figure 19). A significant increase in cell number was 
observed at days 4 and 7 of starvation (2% FBS) in PAX5– cells (Figure 19), while 
these cells have a lower percentage of apoptotic cells at day 3 (Figure 20). IL-6, GP80 
(IL-6 receptor) and GP130 (IL-6 signal transducer) mRNA were significantly increased  
in PAX5– SP53 and Jeko cells compared to controls at day 3 of 2% serum starvation 
(Figure 21A).  
BCL-XL and MCL1 are important anti-apoptotic proteins that are involved in the 
IL-6 signaling cascade (Zushi, Shinomura et al. 1998, Puthier, Bataille et al. 1999), and 
these proteins are often overexpressed in B cell lymphomas (Agarwal and Naresh 
2002, Cho-Vega, Rassidakis et al. 2004). Sphingosine-1-phosphate receptor 1 
(S1PR1) is an important marker for MCL diagnosis (Nishimura, Akiyama et al. 2010) as 
well as a downstream target for IL-6 signaling via STAT3 (Lee, Deng et al. 2010). BCL-
XL, MCL1 and S1PR1 mRNA levels were significantly increased after serum restriction 
in PAX5– MCL compared to controls (Figure 21B).   
SP53 cells have previously been reported to secrete autocrine IL-6 (Zhang, 
Yang et al. 2012). We examined the levels of autocrine IL-6 by ELISA using 
conditioned media of SP53 PAX5– MCL. IL-6 levels were significantly increased in 
conditioned medium PAX5– MCL compared to controls, with HS5 conditioned medium 
serving as a positive control (Figure 22A). Serum restriction was also reported to 
induce IL-6 expression (Zhang, Yang et al. 2012), and nutrient restriction resulted in  
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Figure 20: PAX5– Cells Are Less Apoptotic Under Serum Starved Conditions.  
PAX5– cells demonstrate reduced cell death in low serum conditions. Apoptotic 
evaluation of serum starved PAX5– MCL cells using FACS. Cells were cultured in a low 
serum condition (2% FBS) for 3 days prior to staining with Annexin-V and 7AAD.  
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Figure 21: PAX5– Cells Express Increased IL-6 Family and Target Genes. (A) IL-6 
signaling components were quantitated using qRT-PCR. Cells were cultured in low 
serum condition for 3 days prior to mRNA collection, with relative expression 
normalized to GAPDH. (B) BCL-XL, MCL and S1PR1 gene expression are increased in 
PAX5– cells during culture in 2% RPMI for 3 days. * p < 0.05 (vs. PAX5control; Student’s 
t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Figure 22: SP53 PAX5– Cells Express Increased IL-6. (A) ELISA analyses of IL-6 
using conditioned media from SP53 PAX5– MCL cells or control cells. IL-6 level 
analyses at steady state levels (left) and during serum withdrawal (right). HS5 
conditioned media used as a positive control, which is enriched for IL-6. (B) ELISA 
analyses of Jeko PAX5–  MCL supernatant. * p < 0.05 (vs. PAX5control; Student’s t-test); 
**p < 0.005 (vs. PAX5control; Student’s t-test).    
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markedly increased IL-6 secretion in SP53 PAX5– cells compared to control cells 
(Figure 22A). However, Jeko, which do not produce autocrine IL-6 (Zhang, Yang et al. 
2012), did not show increased IL-6 secretion upon PAX5 silencing or serum starvation 
(Figure 22B). 
SUMMARY 
In summary, we discovered that PAX5 is downregulated in MCL patients, and 
PAX5– MCL cells have a significant proliferative advantage in vitro and in vivo. This is 
significant, as MCL disease prognosis is heavily dependent on disease proliferation.  
We find that PAX5– MCL cells have a similar gene repertoire as Pax5 knockdown 
murine cells, and to exhibit early expression of plasmacytic differentiation genes. This 
deregulation of genes is the possible cause of an increased tumorigenic phenotype 
seen in PAX5– MCL cells.  
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Chapter 4: LOSS OF PAX5 LEADS TO AN INCREASE IN MANTLE CELL 
LYMPHOMA DISSEMINATION AND PROGRESSION 
INTRODUCTION 
Since there was a significant difference between normal and mantle cell 
lymphoma (MCL) PAX5 expression in patients, we postulated if PAX5 epxression might 
affect disease dissemination. Mantle cell lymphoma is characterized as a late stage 
disease, with patients often presenting with stage IV extranodal involvement. MCL can 
disseminate to the bone marrow, gastrointestinal tract, liver and neural tissue (Perez-
Galan, Dreyling et al. 2011). About 30% of MCL patients also present with a leukemic 
phase. Thus, we sought to investigate if differential levels of PAX5 can affect MCL 
dissemination. 
There is clinical evidence regarding the blastoid phenotype of mantle cell 
lymphoma. The blastoid form is said to be rarer, with about 15% of cases being 
reported to be blastoid. Patients exhibiting the blastoid phenotype have significantly 
poorer overall outcome (Bernard, Gressin et al. 2001, Perez-Galan, Dreyling et al. 
2011), and a higher proliferation index leading to a worse prognosis. The blastoid 
variant has also been reported to be drug resistant is characterized by decreased TP53 
expression and a constitutive AKT signaling axis. Both classical and blastoid MCL have 
been implicated in the latter (Rizzatti, Falcao et al. 2005), implicating the importance of 
B cell survival pathways in MCL.  
RESULTS 
Loss of PAX5 causes greater bone marrow engraftment 
Similar to multiple myeloma, MCL cells originated from lymph nodes are 
frequently disseminated to the bone marrow compartments (Salaverria, Perez-Galan et 
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al. 2006).We evaluated the tumorigenic engraftment capacity of PAX5– MCL cells using 
an intravenous (I.V.) xenograft mouse model.  We first transplanted 1 x 106 and 5 x 106 
PAX5– MCL cells or control cells into NOD/SCID mice. After 6-8 weeks, organs were 
isolated from each mouse and evaluated for tumor engraftment by FACS analyses 
using human CD45 and GFP as markers. Statistically higher numbers of CD45+ and 
GFP+ cells were recovered in the PAX5– MCL xenograft mice compared to controls 
(Figure 23). Especially, cell engraftment to the bone marrows was significantly higher 
compared to controls regardless of cell transplant dosage (Figure 23, Figure 24). 
Immunohistochemistry analyses of frozen tissue sections also displayed increased 
numbers of CD45+ cells in PAX5– xenograft bones. Increased dispersal of PAX5– MCL 
cells was found in the bone marrows compared to control SP53 cells (Figure 25) and 
Jeko cells (Figure 26).  
Since we found an increased engraftment and dissemination of PAX5– MCL 
cells in the xenograft bones, we further investigated effects of PAX5 silencing on cell 
adhesion using HS5 human bone marrow stromal cells (BMSCs).  GFP+ PAX5– MCL 
cells were labeled with PKH26 red fluorescence dyes in order to easily track the cells 
(Figure 27, Figure 28). Since the adhesion assay was performed in one hour, it did not 
affect levels of PKH intensity in vitro (data not shown).  Compared to control cells, 
PAX5– MCL cells demonstrated markedly increased cell adhesion to the HS5 BMSC 
monolayer (Figure 29). 
PAX5 loss causes greater MCL dissemination  
While observing PAX5 silenced and control cells in culture, we discovered an 
interesting phenomenon regarding cellular motility. PAX5– cells were more motile 
compared to control cells. We quantitatively measured distances travelled by MCL  
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Figure 23: PAX5– Cells Have Higher Bone Marrow Engraftment in vivo. PAX5– 
MCL cells or control cells were injected into NOD/SCID mice (n=22) via I.V. injection at 
two different dosages (1 x 106 and 5 x 106). After 8 weeks, xenograft mice were 
sacrificed. Bone marrows (from femurs and tibias) and spleens were collected and 
stained for human leukocyte cells using anti-CD45 antibody. * p < 0.05 (vs. PAX5control; 
Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Figure 24: PAX5– Cells Engraft More To the Bone Marrow. Representation of FACS 
analyses of bone marrow cells from PAX5– MCL (5x106) injected xenograft mice. 
Higher numbers of GFP+CD45+ cells are noted in PAX5– xenografts compared to 
controls. Both PAX5– and control mice were sacrificed at the same time. 
  
Jeko 
5 x 10
6
 xenograft 
 
SP53 
5 x 10
6
 xenograft 
PAX5control PAX5
-
 
 
  
 
PAX5control PAX5
-
 
 
  
GFP+CD45+ GFP+CD45+ 
GFP+CD45+ GFP+CD45+ 
GFP+CD45+ GFP+CD45+ 
GFP+CD45+ GFP+CD45+ 
CD45 
G
F
P
 
CD45 
G
F
P
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Increased Tumor Cell Engraftment in SP53 PAX5– Xenograft Mice. 
Representative confocal images of the bone sections of xenograft mice. Increased 
CD45 and GFP positive cells  in host tissue (bone marrow). Arrows indicate CD45 and 
GFP positive cells. Scale bar, 100µm. 
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Figure 26: Increased Tumor Cell Engraftment in Jeko PAX5– Xenograft Mice. 
Representative confocal images of the bone sections of xenograft mice. Increased 
CD45 and GFP positive cells  in host tissue (bone marrow). Arrows indicate CD45 and 
GFP positive cells. Scale bar, 100µm. 
 
PAX5control PAX5
-
 
Jeko 
B
o
n
e
 m
a
rr
o
w
s
 
B
o
n
e
 m
a
rr
o
w
s
 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: SP53 PAX5– Cells Exhibit Increased Bone Marrow Adhesion. Control or 
PAX5– SP53 cells were stained with PKH26 and subsequently seeded onto a pre-
established monolayer of HS5 bone marrow stromal cells. Arrows point to PKH26+ 
cells. Scale bar, 200µm. 
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Figure 28: Jeko PAX5– Cells Exhibit Increased Bone Marrow Adhesion. Control or 
PAX5– Jeko cells were stained with PKH26 and subsequently seeded onto a pre-
established monolayer of HS5 bone marrow stromal cells. Arrows point to PKH26+ 
cells. Scale bar, 200µm. 
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Figure 29: Increased Bone Marrow Adhesion in PAX5– Cells. In vitro adhesion of 
lymphoma cells to HS5 BMSCs was calculated by measuring PKH26 dye intensity 
relative to fluorescent reading of inputs. Each value represents the mean ± S.D (n=6).  
* p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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PAX5– and control cells over 2 days using time lapse video microscopy. Distances (m) 
traveled by PAX5 silenced SP53 and Jeko cells, which were averaged of results from 
18 different wells, were far greater compared to control cells (Figure 30). PAX5– MCL 
cells also displayed a greater sense of motility overall – on average PAX5– MCL cells 
were significantly faster than control cells (Figure 31). When analyzing for the maxima 
(replicate with highest motility) and minima (replicate with lowest motility) of speed, we 
find that PAX5– MCL cells have greater amplitudes for velocity than control cells, 
suggesting a greater rate of motility (Figure 31).  
To investigate the role PAX5 has in dissemination in vivo, we transplanted SP53 
cells via subcutaneous injection into NOD/SCID hosts. As observed, PAX5– SP53 
xenograft mice developed larger tumors compared to controls (Figure 16A). Using 18F-
FDG uptake, we successfully determined PAX5– xenografts having more dissemination 
sites infiltrated with tumor cells (Figure 32). All PAX5– xenografts had tumor cell 
infiltration of the thymus, bone marrow or spleen. We also analyzed gastrointestinal 
track (GIT) harvested organs from SP53 PAX5– xenografts for tumor cell infiltration. 
PAX5– xenografts had significantly higher counts than control xenografts (Figure 33A). 
Interestingly, we noticed that 5 patients reported to have GIT involvement have 
significantly lower levels of PAX5 transcript (Figure 33B) as well, implying that 
downregulation of PAX5 expression might be an important event in MCL dissemination.  
Within MCL samples, PAX5 levels in CD19+ cells from bone marrows were 
significantly decreased compared to blood samples (Figure 34). This supports our 
observation that PAX5– MCL cells have increased bone marrow engraftment in vivo. 
When we compared paired (blood and bone marrow) MCL samples from two patients,  
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Figure 30: PAX5– Cells Have Increased Motility in Vitro. PAX5– MCL cells were 
stained with PKH26 and subsequently tracked over 24 hours using time lapse video 
microscopy. Total average distance moved for PAX5– and control MCL cells was 
measured, with PAX5– cells moving further on average. Movement of single cells 
(n=18) were tracked using the Amira software. * p < 0.05 (vs. PAX5control; Student’s t-
test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Figure 31: PAX5– Cells Have Greater Maximum Velocity in vitro. (Top) Average 
distance moved for PAX5– and control MCL over time. (Bottom) The fastest moving 
replicate (SpeedMax), slowest moving replicate (SpeedMin) and average (SpeedAverage) 
was compared between SP53 PAX5– and control MCL cells. Distance moved was 
plotted against time.    
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Figure 32: Increased Tumor Cell Dissemination in SP53 PAX5– xenograft mice. 
18F-FDG counts of common MCL dissemination organ sites from SP53 PAX5– or 
control subcutaneous xenografts. (%) ID / g of each target organ was normalized to (%) 
ID / g of muscle tissue. ID/g = injected dose / gram, LN = lymph node. Dotted box 
highlights target organs with  at least twice the amount of muscle 18F-FDG uptake. Sub-
cu = subcutaneous, LN = lymphnode. 
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Figure 33: Increased GIT Dissemination in SP53 PAX5– Xenograft Mice. (A) 18F-
FDG counts of GIT harvested organs from SP53 PAX5– or control subcutaneous 
xenografts. (%) ID / g of each target organ was normalized to (%) ID / g of muscle 
tissue. ID/g = injected dose / gram (B) CD19+ cells isolated from MCL GIT-involved 
patients (n=5) contained lower levels of PAX5 mRNA compared to CD19+ cells from 
MCL non-GIT patients (n=26). Each group represents the mean ± S.D. * p < 0.05 (vs. 
PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
  
Stomach Liver Intestine
0.0
0.5
1.0
1.5
2.0
SP53.PAX5
control
SP53.PAX5
-
*
*
O
rg
a
n
 /
 m
u
s
c
le
ra
ti
o
SP53 
0.0
0.5
1.0
1.5
2.0
Non-GIST involvment
GIST involvment
**
R
e
la
ti
v
e
 P
A
X
5
 
e
x
p
re
s
s
io
n
 
CD19+  
MCL blood  
CD19+  
MCL blood 
A B 
70 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Decreased PAX5 Levels in CD19+ Bone Marrow MCL Cells. (Left) CD19+ 
B cells were isolated from MCL blood or apharesis samples (n=31) or from bone 
marrows of or MCL patients (n=8) and PAX5 mRNA levels determined via qRT-PCR. 
Each replicate was run in triplicate with values normalized to GAPDH. (Right) Two 
patients with paired peripheral blood and bone marrow were analyzed for PAX5 mRNA 
levels. CD19+ bone marrow cells had less PAX5 transcript compared to peripheral 
blood when comparing within the same patient. * p < 0.05 (vs. PAX5control; Student’s t-
test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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we find that PAX5 expression of CD19+ cells from the bone marrow was significantly 
reduced compared to PAX5 expression of peripheral blood in both patients (Figure 34).  
In order to find relevancy in xenograft models, we transplanted unmanipulated 
(parental) SP53 MCL cells into mouse xenograft host via subcutaneous injection and 
evaluated PAX5 levels of dispersed human cells harvested from the spleen or bone 
marrows of xenograft mice. PAX5 levels are significantly lower in human cells isolated 
from the spleen and bone marrows, when compared to the parental subcutaneous 
tumors (Figure 35). This again points to PAX5 downregulation being an important 
event in MCL dissemination. Overall, our data implicates loss of PAX5 expression 
involvement in MCL organ dissemination. 
PAX5 expression as a predictor for aggressive MCL 
The median survival of MCL ranges from 3-5 years. The blastoid variant type of 
MCL is a highly aggressive but a rare form of MCL and demonstrates a worse 
prognosis than the common forms of MCL (Argatoff, Connors et al. 1997, Bosch, 
López‐Guillermo et al. 1998, Bernard, Gressin et al. 2001). Analysis of samples 
revealed that blastoid types contained significant reduced levels of PAX5 compared to 
non-blastoid cases (Figure 36). We found that overall survival of patients with PAX5low 
was significantly lower than survival of patients with PAX5high (Figure 37), even when 
stratifying for PAX5 levels in two different manners; PAX5low were either classified as 
bottom 25% or 50%. PAX5low patients exhibited survival rates very similar to that of 
verified blastoid survival cases within our data set (Figure 38), suggesting PAX5 levels 
can be used to predict survival within advanced MCL patients.  Collectively, our data  
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Figure 35: PAX5 Is Downregulated in Disseminated Cells. A total of 3x 106 
unmanipulated SP53 parental cells were injected subcutaneously into host xenografts 
and PAX5 mRNA expression determined from isolated human cells 6 weeks post 
injection. Human cells were isolated from the host tumor, spleen and bone marrow with 
PAX5 mRNA levels were determined via qRT-PCR. Each replicate was run in triplicate 
with values normalized to GAPDH. * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 
0.005 (vs. PAX5control; Student’s t-test).    
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Figure 36: MCL Blastoid Variants Have Significantly Reduced PAX5 expression. 
CD19+ cells isolated from MCL blastoid patients (n=12) contained lower levels of PAX5 
mRNA compared to CD19+ cells from MCL non-blastoid patients (n=19). Each group 
represents the mean ± S.D. * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. 
PAX5control; Student’s t-test).   * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 
(vs. PAX5control; Student’s t-test).    
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Figure 37: PAX5low MCL Patients Have Significantly Poorer Overall Survival. 
Overall survival of MCL patients were significantly decreased in PAX5low populations 
compared to PAX5high populations. (Left) Samples were stratified to be top 75% = 
PAX5high, bottom 25% = PAX5low. (Right) Samples were stratified to be top 50% = 
PAX5high, bottom 50% = PAX5low. All analyses were significant (p-value < 0.05 Mantel-
Cox curve analysis).    
  
S u rv iv a l o f  F in a l u p  to  1 0 0 0  d a y s  P A X 5  2 5 % :S u rv iv a l p ro p o r t io n s
0 5 0 0 1 0 0 0 1 5 0 0
0
5 0
1 0 0
P A X 5
l o w
P A X 5
h i g h
D a y s
P
e
rc
e
n
t 
p
a
ti
e
n
t 
s
u
rv
iv
a
l*
S u rv iv a l p ro p o r t io n s : S u rv iv a l o f F in a l u p  to  1 0 0 0  d a y s  P A X 5  5 0 %
0 5 0 0 1 0 0 0 1 5 0 0
0
5 0
1 0 0
P A X 5
l o w
P A X 5
h i g h
D a y s
P
e
rc
e
n
t 
p
a
ti
e
n
t 
s
u
rv
iv
a
l*
Overall survival based on PAX5 
expression (50%) 
Overall survival based on PAX5 
expression (25%) 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: MCL Blastoid Variants Have Significantly Poorer Overall Survival. 
Patients with blastoid type MCLs demonstrate a poor overall survival compared to 
patients with non-blastoid MCL. A total 20 patients were evaluated, with blastoid (n=10) 
and classical (n=10) cases analyzed for overall survival. *p-value < 0.05 Mantel-Cox 
and Gehan-Breslow-Wilcoxon. 
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support PAX5 down-regulation is an important signaling event in MCL that contribute to 
increased progression and dispersal.  
PAX5– have increased AKT, ERK and pSTAT3 signaling 
PAX5– MCL cells expressed increased levels of positive cell cycle regulators 
such as CDKs and cyclins, and decreased levels of negative cell cycle regulators such 
as TP53 and CDKN1A (Figure 18). In order to find molecular pathways that contribute 
to the growth of PAX5– MCL, we first examined pathways that have been known to be 
expressed in different hematological malignancies such as the PI3K/AKT/mTOR 
signaling axis and MAPK/ERK pathway (Dal Col, Zancai et al. 2008, Psyrri, 
Papageorgiou et al. 2009, Wang, Atayar et al. 2009, Dennison, Shanmugam et al. 
2010, Carlo-Stella, Locatelli et al. 2013). Immunoblots showed highly activated 
signaling components involved in AKT/mTOR pathways such as pmTOR, p-p70 and 
pAKT, which could account for an increase in proliferation exhibited by PAX5– MCL 
cells (Figure 39). pERK and pMAPK have been implicated in cell survival, adhesion to 
the microenvironment as well as motility (Kolch 2005), and we also observed an 
increase of these proteins in PAX5– MCL cells (Figure 39). Cyclin D1, a genetic 
hallmark for MCL, was also upregulated in PAX5– MCL cells (Figure 39) (Bea, 
Salaverria et al. 2009). CCND3, which encodes for cyclin D3, has been previously 
reported to be critical in B cell lymphopoiesis (Cooper, Sawai et al. 2006), and has 
been implicated in compensating for loss of cyclin D1 function in MCL (Rosenwald, 
Wright et al. 2003). Here, we report that PAX5– MCL and non-MCL B cell cells express 
increased CCND3 transcripts (Figure 40). 
Since we observed an increase of PAX5– cells engraftment to the bone marrow, 
we determined if PAX5 expression can affect MCL response to the bone marrow  
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Figure 39: Increased MCL Signaling Pathway Proteins PAX5– cells. Immunoblot 
analyses of pmTOR, p-p70, p-AKT, pERK (p42/44) and pMAPK (p38) in control and 
PAX5– MCL cells with β-actin serving as the loading control. 
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Figure 40: PAX5– Cells Express Increased Amounts of CCND3. Semi quantitative 
RT-PCR analysis CCND3 upon PAX5 silencing in MCL and non MCL B cells. GAPDH 
serves as a loading control. 
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microenvironment. We used conditioned media from HS5 human BMSCs which are 
enriched for IL-6 (Delk and Farach-Carson 2012), an alternative source of paracrine IL-
6. HS5-conditioned medium was supplemented to growth media and the cells allowed 
to grow in culture for 3 days. At steady state (0 hours), PAX5– MCL constitutively 
expressed higher levels of phosphorylated STAT3 which was largely increased upon 
HS5 addition compared to controls (Figure 41), suggesting PAX5– cells exhibit a 
phenotype that is more sensitive to bone marrow microenvironmental cues.   
SUMMARY 
In summary, we found PAX5– cells significantly engraft more to the bone 
marrow, while displaying increased adhesion to human BMSCs in vitro. PAX5 was also 
found to be downregulated in MCL patient bone marrow compared to peripheral blood. 
This was corroborated by our finding that PAX5– xenografts have greater tumor 
infiltration of the bone marrow and that PAX5 downregulation is an important step in in 
vivo MCL dissemination. Critically, we also report that PAX5 expression is a predictor 
for the blastoid phenotype, and that its expression could be used as a means for 
survival prognosis.   
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Figure 41: PAX5– Cells Have Increased pSTAT3 Signaling in BM Conditioned 
Media. Immunoblot analyses of pSTAT3 expression in PAX5– and control MCL cells 
upon incubation with HS5 conditioned medium during culture. HS5-CM was added to 
culture for up to 3 days prior to protein collection. Total STAT3 and β-actin served as 
loading controls. 
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Chapter 5: PAX5 EXPRESSION AFFECTS MANTLE CELL LYMPHOMA DRUG 
SENSITIVITY 
INTRODUCTION 
Mantle cell lymphoma is a disease marked with increased therapeutic 
resistance. MCL patients often present with advanced disease, and 20-80% achieves 
complete remission. However, a high majority of patients suffer relapse, pointing to 
MCLs harboring a subpopulation of cells that are drug resistant clones that have the 
ability to reconstitute the disease over time (Jung, Chen et al. 2011).  
Bortezomib is a proteasome inhibitor that has found clinical success in multiple 
myeloma and in mantle cell lymphoma (O'Connor, Moskowitz et al. 2009) is used as a 
second line treatment option in patients that have failed the first course of treatment. 
Bortezomib functions by eliciting the unfolded protein response (UPR) in cells, thus 
leading to cell apoptosis via NOXA upregulation (Perez-Galan, Roue et al. 2006). 
However, there are reported cases where second line therapy of bortezomib failed to 
clear the disease (Suh and Goy 2008), hinting again to a population of MCL cells that 
are highly drug resistant. 
To further decipher the drug resistance properties of our cells, we performed a 
high throughput screen (HTS) of 3864 compounds on Jeko and SP53 control and 
PAX5– MCL cells. This screen was performed to elucidate the role differential PAX5 
expression might have in MCL disease resistance, which is a common hallmark of 
MCL. Critically, there has not been a previous study employing a HTS of clinical and 
novel compounds in targeting MCL cells. As such, much was garnered regarding MCL 
biology and physiology through this HTS.   
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RESULTS 
PAX5 affects drug resistance in vitro 
        Doxorubicin and etoposide are chemotherapeutic agents that can induce p53 
derived cell damage responses (Karpinich, Tafani et al. 2002, Manna, Gangadharan et 
al. 2012).  When SP53 was treated with doxorubicin, an impaired response in TP53 
transcription was observed in PAX5– MCL cells (Figure 42A) (Dai, Tang et al. 2011). 
TP53 transcript levels increased significantly within 24 hours of doxorubicin treatment 
in control cells (Figure 42A). RT-PCR analyses also showed that after 6 and 12 hours 
of etoposide treatment PAX5– cells have lower levels of TP53 transcript (Figure 42B). 
As predicted from TP53 expression responses after drug treatment, PAX5– SP53 cells 
were more resistant to treatment of doxorubicin (Figure 43). 
       Since PAX5– MCL cells showed increased resistance compared to controls (Figure 
42 and 43), we further investigated roles of PAX5 in drug resistance of MCL using a 
clinically relevant reagent, bortezomib. Bortezomib inhibits proteasome activities and is 
widely used to treat MCL, albeit with varying clinical efficacy due to drug-resistant 
tumor cells (Suh and Goy 2008). PAX5– MCL cells showed increased resistance to 
bortezomib and bortezomib contained regimens (Figure 44).  A recent study showed 
that MCL cell lines and unfractionated primary MCL cells differentiate into plasma-like 
cells after exposure to bortezomib (Pérez-Galán, Mora-Jensen et al. 2011). These 
bortezomib-resistant cells show elevated expression of CD138, CD38 and BLIMP1, 
and lack CD19. PAX5– cells have increased CD138 and BLIMP1 expression (Figure 6 
and 7). PAX5 normally represses BLIMP1 expression and promotes CD19 expression 
during normal B cell development (Johnson, Shapiro-Shelef et al. 2005), suggesting  
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Figure 42: PAX5– SP53 Cells Have a Delayed TP53 Response to DNA Damage. (A) 
Delayed TP53 upregulation in PAX5– MCL cells in response to DNA damaging agents. 
PAX5– MCL cells were treated with doxorubicin (500nM) and etoposide (200nM) for 24 
hours and TP53 mRNA expression was evaluated by qRT-PCR. GAPDH served as a 
loading controls for PCR experiments. (B) TP53 expression in response to etoposide. 
Cells were treated with etoposide (200nM) for 6 and 12 hours and TP53 expression 
was evaluated by semi-quantitative RT-PCR. * p < 0.05 (vs. PAX5control; Student’s t-
test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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Figure 43: PAX5– SP53 Cells Are More Resistant to Doxorubicin. PAX5– cells are 
more resistant to doxorubicin. Cells were treated with doxorubicin for 48 to 96 hours 
and cell viability was analyzed using CTB® assays. Each value represents the mean ± 
S.D (n=3). * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; 
Student’s t-test).    
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Figure 44: PAX5– Cells Are More Resistant to Bortezomib. PAX5– and control MCL 
cells were treated either with bortezomib or a bortezomib combined regiment (80nM 
bortezomib, 4µg/mL doxorubicin and 40µg/mL dexamethasone) for 24 hours. Cellular 
viability was measured using CellTiterBlue™. Each value represents the mean ± S.D 
(n=3). * p < 0.05 (vs. PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s 
t-test).    
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that PAX5 down-regulation may be an important event for bortezomib resistance in 
MCL. 
High-throughput screen of 3864 compounds 
To profile for functional therapeutic targets against our highly aggressive PAX5– 
populations, a high-throughput screen (HTS) of 3864 compounds was performed using 
the two MCL cell lines (SP53 and Jeko). Prior to the start of the screen, growth 
conditions for each cell line used were measured to ensure optimization of our HTS, 
where differences in compound toxicity could be replicated with high reproducibility and 
sensitivity. Cells were seeded at varying densities and cell number measured over 
three or four days either through the use of proliferative assays (CellTiterBlue™ 
PROMEGA) or through direct imaging of cells stained with nucleic acid dyes (data not 
shown). As we plan to use a robotic platform to facilitate our HTS, a positive control to 
ensure consistent compound transfer from stock to assay plates needed to be 
determined.  
Six compounds were chosen for their use in general cell cytotoxicity – paclitaxel, 
anisomysin, carbonyl cyanide m-chlorophenyl hydrazine (CCCP), etoposide, 
doxorubicin and doxetaxel (Figure 45). All compounds are common cell cytotoxic 
inducers and would serve as ideal positive controls for our HTS. Three of the 
compounds were further analyzed for consistency in inhibition across all cell lines 
(Figure 46). Finally, reproducibility assays were conducted with our chosen positive 
control (doxorubicin) so that a clear distinction between signals (positive controls, 
positive hits) and that to noise (negative controls, negative hits) of our HTS could be 
recorded.  
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Figure 45: 6-Compounds Evaluation for HTS Positive Control Selection. Cells 
were incubated with log fold dilutions of paclitaxel, anisomysin, CCCP, etoposide, 
doxorubicin and doxetaxel to determine a compound that could be used as a general 
cytotoxic agent in our HTS.  
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Figure 46: Further Evaluations of Cytotoxic Compounds for the HTS. 
Doxorobucin, Anisomycin and CCCP were compared and doxorubicin found to be the 
best compound to be used as a positive control for the HTS. Red lines are PAX5– 
replicates, black lines are PAX5control replicates. Solid lines are replicates #1, and 
dashed lines are replicates #2.  
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High throughput screening (HTS) has been a tool for novel drug discovery; 
however, no reported screenings were performed using only MCL cells. In order to 
understand the drug resistant nature of PAX5 silenced MCL in a comprehensive way, 
we screened 3864 compounds from three different libraries; a custom made library of 
clinically relevant compounds (Custom Clinical, 246 compounds), a bioactive library 
containing FDA approved compounds (Prestwick, 1200 compounds) and an NCI 
diversity library containing compounds currently in development or clinical trials (NCI 
Diversity library, 2418 compounds) (Figure 47). A consistent Z’ score of >0.5 across 
different screening days indicated that the screen was consistent and reliable. A good 
separation between signal and noise was achieved in all three libraries screened, with 
a scatterplot graph for each cell type depicting a clear distinction between control and 
test compounds (Figure 48A - C). Doxorubicin served as positive controls in all our 
screens, with DMSO serving as the negative control and media only wells serving as 
blanks (Figure 48A - C). Indeed for reproducibility, when we further analyzed for 
independent replicates we find that compounds were relatively consistent over two 
across the different libraries. Plotting for values for replicate #1 as the Y-axis, and the 
values for replicate #2 as the X-axis, we can determine that most compounds follow a 
linear trend (Figure 48D, data not shown), indicating reproducibility over two 
replicates.  
PAX5– MCL cells have increased compound resistance 
Compounds that have a difference in efficacy of at least 5% between control and 
PAX5– MCL were analyzed. After filtering the compounds that have at least a 40% 
inhibitory effect of doxorubicin (HTS positive control), we were left with a positive 
compound hit rate of 3.7% - 7.0% for the HTS libraries. Across all three libraries,  
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: Three Unique Compound Libraries in the HTS. A Pie chart summarizing 
sources for compounds used in the HTS study comprising of three unique library sets; 
a custom made library of clinically relevant compounds (Custom Clinical, 246 
compounds), a bioactive library containing FDA approved compounds (Prestwick, 1200 
compounds) and an NCI diversity library containing compounds currently in 
development or clinical trials (NCI Diversity library, 2418 compounds).   
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Figure 48: HTS Compound and Internal Control Distribution. (A-C) Signal to noise 
ratio of HTS screening. Scatter plots represent percent of activity inhibition of positive 
controls (green), negative controls (red) and test compounds (black) relative to vehicles 
in four cell types. Custom Clinical library data show in A, Prestwick data show in B and 
NCI diversity library data show in C.(D) NCI Diversity library normalized data for SP53 
(top) and Jeko (bottom) parental cells, Y axis = Replicate #1, X axis = Replicate #2.  
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PAX5– MCL cells were highly more resistant compared to controls (Figure 49). In 
SP53, only 30-40% of compounds demonstrated effective growth inhibition in PAX5–
cells, whereas 60-70% of compounds were effective in controls. In Jeko, only less than 
10% compounds were effective in inhibiting PAX5– MCL, whereas 90-100% 
compounds inhibited growth of controls (Figure 49). Further analysis revealed unique 
compounds that were more resistant in killing PAX5– cells (Figure 50, Figure 51, 
Figure 52), selected for by significance as detailed in Chapter 2.These compounds 
exhibit a 10% difference cytotoxic inhibition between control and PAX5– cells, and were 
not screened for a minimum of 40% cell inhibition. As such, identification of unique 
compounds targeting different pathways can be uncovered to through target validation 
of our libraries. 
To validate such a methodology, we chose to concentrate on the custom clinical 
library data set. Jeko cells are more resistant to compounds than SP53 cells (Figure 
49), thus we further evaluated the custom clinical dataset for Jeko cells, and found that 
there was a similar trend for compound sensitivity over the two independent replicates 
(Figure 53). PAX5– Jeko cells exhibited greater sensitivity to only 7 – 14% of 
compounds screened from the library, as compared to 29% - 52% of controls. 
Interestingly, we found that compounds from the Custom Clinical library targeting the 
PI3K-AKT-mTOR and MEK/ERK signaling cascade were less effective in PAX5–Jeko 
cells compared to control cells (Figure 54). Analysis was determined by comparing two 
independent replicates of the screened library, with overlapping and non-overlapping 
compounds summarized for pathway activity (Figure 54). A similar trend was also 
observed in PAX5– SP53 cells (Figure 55), suggesting PAX5– MCL cells have a higher 
expression of the common MCL signaling cascade (Figure 39), leading to resistance of  
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Figure 49: HTS Reveals Drug Resistance Nature of PAX5– MCL Cells. Distribution 
of the compounds in HTS that are cytotoxic to each cell type. There were significantly 
more compounds that inhibited proliferation of control cells than PAX5– cells. 
Compounds that had  >40% efficacy were classified as positive hits, and differences 
between control and PAX5– cells (minimum of 5% cell cytotoxicity) analyzed. 
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Figure 50: PAX5– Cells Are More Resistant to Compounds from the Custom 
Clinical Library. Custom clinical library exhibiting compounds with >10% (light gray) 
and >20% (dark gray) differences between control and PAX5–  MCL cells. 
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Figure 51: PAX5– Cells Are More Resistant to Compounds from the Prestwick 
Library. Prestwick library of compounds with >10% (light gray) and >20% (dark gray) 
differences between control and PAX5–  MCL cells. 
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Figure 52: PAX5– Cells Are More Resistant to Compounds from the NCI Diversity 
Library. NCI Diversity library featuring compounds with >20% (light gray) and >30% 
(dark gray) differences between control and PAX5–  MCL cells. 
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Figure 53: Increased Compound Resistance in Jeko PAX5– Cells. Jeko PAX5– cells 
were more resistant to compounds screened in the Custom Clinical Library over two 
replicates (n=2). Reproducibility between independent replicates indicated a drug 
resistant trend for Jeko PAX5– cells. 
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Figure 54: Jeko PAX5– Cells Are More Resistant to PI3K/Mtor and AKT Inhibition. 
Jeko PAX5– cells were more resistant to compounds screened in the Custom Clinical 
Library (n=2). Inhibitors against the PI3K/mTOR and AKT/MEK/MAPK were less 
sensitive in inducing cytotoxicity in PAX5– MCL cells. Array represents compounds 
targeting components of aforementioned pathways over two different replicates.   
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Figure 55: SP53 PAX5– Cells Are More Resistant to PI3K/Mtor and AKT Inhibition. 
SP53 PAX5– cells were more resistant to compounds screened in the Custom Clinical 
Library (n=2). Inhibitors against the PI3K/mTOR and AKT/MEK/MAPK were less 
sensitive in inducing cytotoxicity in PAX5– MCL cells. Array represents compounds 
targeting components of aforementioned pathways over two different replicates.   
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targeting the pathway. Indeed, when averaging both independent replicates, Jeko 
PAX5– demonstrated an overall increase of resistance against select compounds 
targeting PI3K, mTOR, MEK and MAPK (Figure 56). 
MEK has been implicated in tumor cell adhesion (Pals, de Gorter et al. 2007), 
and we observed an increase in PAX5– MCL cells adhering to bone marrow stromal 
cells in vitro and in vivo (Figure 25-29) . Since we discovered that PAX5– MCL cells 
were resistant to MEK inhibitors (Figure 54-56) and have an upregulation of MEK 
downstream targets (Figure 39), we postulated that MEK inhibition might affect 
lymphoma cell adhesion. Indeed, we report that Selumetinib (AZD6244) was highly 
efficient in inhibiting cellular bone marrow adhesion of PAX5–  MCL cells (Figure 57A), 
with no adverse effect on cell viability (data not shown). Selumetinib is a MEK1/2 
inhibitor, that has been studied in other B cell lymphomas (Bhalla, Evens et al. 2011, 
Lv, Zhang et al. 2014) as well as other tumor types (Migliardi, Sassi et al. 2012, El 
Touny, Vieira et al. 2014), however, no studies investigated its effects on adhesion to 
BMSCs. Various doses of selumetinib was used to compare adhesion of PAX5– MCL 
and control cells, and we found that selumetinib only affected PAX5–  adhesion (Figure 
57B). Furthermore, it is interesting to point out that selumetinib is ususally used in 
combination with another compounds to target advanced metastatic diseases 
(Migliardi, Sassi et al. 2012). 
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Figure 56: Jeko PAX5– Cells Are More Resistant to PI3K, Mtor, MEK and MAPK 
Inhibitors. PAX5– MCL Jeko cells are more resistant to the compounds targeting the 
PI3K, mTOR, MAPK and MEK pathways over two replicates. Summary of average 
proliferation inhibition of selected compounds found in the Custom Clinical Library.  
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Figure 57: AZD6244 Reduced Bone Marrow Adhesion of PAX5– Cells in vitro. (A) 
Selumetinib inhibited SP53 and Jeko PAX5– cellular adhesion to HS-5 bone marrow 
stromal cells. Adhesion of lymphoma cells was calculated by measuring PKH-26 dye 
intensity relative to fluorescent reading of inputs. Each value represents the mean 
±S.D. (n=6 (B) AZD6244 only disrupted adhesion in PAX5– Jeko cells. * p < 0.05 (vs. 
PAX5control; Student’s t-test); **p < 0.005 (vs. PAX5control; Student’s t-test).    
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SUMMARY 
PAX5– cells were more resistant to low dose of doxorubicin and bortezomib 
treatment, and a HTS of 3864 compounds ascertained the drug resistant properties of 
PAX5– cells compared to control cells, suggesting PAX5 downregulation as an event in 
MCL drug resistance gain. PAX5– cells exhibited increased compound resistance 
against PI3K, mTOR, AKT and MEK inhibitors, corroborating our observation of 
increased signaling of this pathway.  
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Chapter 6: GENERAL DISCUSSION 
PAX5 is a Novel Tumor Suppressor in Mantle Cell Lymphoma  
Despite its essential role in determining and maintaining B cell identity in mice 
(Cobaleda, Schebesta et al. 2007), functions of PAX5 in human B malignancies have 
been unclear. We discovered that there were quantitative differences of PAX5 
expression among normal B cells and B cells from MCL patients, which displayed 
decreased levels of PAX5 in MCL (Figure 1). Within MCL patients, the PAX5 levels 
were decreased in bone marrows compared to blood (Figure 34). In xenograft mice, 
subcutaneous MCL tumors contained higher PAX5 levels compared to MCL cells from 
host bone marrow (Figure 35). However, PAX5 expression was not absent in MCL 
patients, suggesting that even reduced PAX5 levels are sufficient to induce global 
changes in gene expression for malignant transformation. Our data support 
downregulation of PAX5 in MCL an important step for conversion to a more aggressive 
phenotype (Figure 58). 
PAX5 Affects MCL Cellular Proliferation  
In order to mimic PAX5 levels in MCL patients, we generated MCL cells that are 
stably knocked down for PAX5.  PAX5 levels in Jeko and SP53 were lower than normal 
B cells (Figure 1); we further downregulated PAX5 in these cells to investigate 
differential expression of PAX5 in MCL. PAX5– MCL cells displayed markedly 
increased cellular proliferation in vitro and in vivo, whereas overexpression led to 
delayed growth and cell death (Figure 12).  Increased cell proliferation was 
accompanied by changes to the cell cycle and several cell cycle related genes, such as 
increased cyclin dependent kinases and decreased expression of tumor suppressor  
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Figure 58: Roles PAX5 Signaling Has in MCL Development and Progression. A 
model diagram depicting observations made in the study; downregulation of PAX5 
leads to increased proliferation, dissemination and drug resistance in MCL. 
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genes. Expression of cyclin D1, a genetic hallmark for MCL, was also increased upon 
PAX5 silencing (Figure 39). However, given that cyclin D1 is not sufficient to induce 
lymphomas in mice (Adams, Harris et al. 1999), it is likely that collective changes in 
upregulation of cell cycle promoting genes and downregulation of cell cycle inhibitory 
genes such as Rb, p53, p21 and p27 contributed to increased proliferation of PAX5– 
MCL cells. Increased cellular proliferation and genomic replication due to loss of PAX5 
could potentially lead to increased genomic instability within MCL cells. This further 
exemplifies the importance of tumor proliferation as prognostic factor in MCL 
(Rosenwald, Wright et al. 2003, Tiemann, Schrader et al. 2005), as a positive feedback 
cycle of unchecked replication leading to mutation gains could lead to MCL 
progression. 
 PAX5– MCL cells also utilized existing MCL survival pathways such as 
AKT/mTOR and MAPK/ERK to promote their growth. It is likely that IL-6 is upstream of 
these pathways, since PAX5– SP53 cells produced IL-6 (Figure 22). Investigation of 
the possible role of the platlet-derived growth factor receptor (PDGFR) and epithelial 
growth factor receptor (EGFR) have on PAX5– MCL signaling should be further 
explored, based on the findings of our HTS data (Figure 54). We find that PAX5– MCL 
cells were more resistant to compounds targeting the PDGFR and EGFR pathway. 
PDGFR has been implicated in increased AKT and STAT3 signaling (Laimer, Dolznig 
et al. 2012), and both EGFR and PDGFR have previously been reported to synergize 
with IL-6 signaling, possibly leading to IL-6 signal sensitivity (Wu, Palmer et al. 2008, 
Colomiere, Ward et al. 2009, Wang, van Boxel-Dezaire et al. 2013). IL-6 related 
downstream genes were increased even in Jeko cells which do not produce IL-6, 
suggesting that PAX5 can influence IL-6 related gene expression. In MM KAS 6/1 cells, 
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IL-6 addition leads to methylation of TP53 promoter, resulting in decreased TP53 
expression levels (Hodge, Peng et al. 2005), an event which we observed in SP53 
PAX5– cells as well. Therefore, PAX5 deregulation in MCL could lead to increased 
sensitivity to survival signals, and provide for increased cellular proliferation that was 
observed in low serum conditions.  
The main source of paracrine IL-6 is likely bone marrow stromal cells. Culturing 
PAX5– MCL cells with HS-5 conditioned medium led to upregulation of pSTAT3 
signaling (Figure 40). Advanced MCL patients often present with involvement of 
extranodal sites such as the bone marrow, hinting that in order for malignant cells to 
survive in tissues other than the tissue of origin, adaptation to the local 
microenvironment is necessary. Increased sensitivity to BM growth factors upon PAX5 
silencing could provide survival advantages to MCL cells. Therefore, downregulation of 
PAX5 could be an adaptation process cells to survive in a foreign microenvironment.   
Pax5-/- pro-B cells exhibit increased lineage plasticity and ability to differentiate 
into functional macrophages, granulocytes, dendritic cells, osteoclasts and natural killer 
cells in vivo (Mikkola, Heavey et al. 2002, Schaniel, Bruno et al. 2002). Adoptive 
transfer of Pax5-/- B cells into immunodeficient mice led to development of T cells, 
indicating Pax5 down-regulation confers mature B cells to acquire plasticity similar to 
early progenitor cells. We did not test direct lineage differentiation of PAX5– MCL due 
to other oncogenic mutations that were present, however, MCL cells largely increased 
colony forming ability in PHA-LCM medium upon PAX5 silencing (Figure 8). In 
addition, PAX5– MCL cells had increased PKH26 retention when injected into xenograft 
hosts, indicating that PAX5 silencing in MCL affects the quiescent cell population that 
retain the lipophilic dye. This methodology of PKH labelling was utilized to isolate long 
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term HSCs as well as cancer stem cells (Pece, Tosoni et al. 2010). Our data support 
PAX5 downregulation promote MCL cells to more stem-like, however, detailed 
molecular mechanisms should be evaluated by RNA-seq or CHIP-seq.  
PAX5 Affects MCL Dissemination and Bone Marrow Adhesion 
We observed MCL BM samples had significantly lower amounts of PAX5 when 
compared to MCL peripheral blood (Figure 34). This is highly interesting as extranodal 
bone marrow involvement is a common MCL event (Jares, Colomer et al. 2007), and 
there have been no reports on PAX5’s role in lymphoma dissemination. We found that 
PAX5– cells had increased adhesion to bone marrow stroma in vitro, and we employed 
two different methodologies for in vivo engraftment and dissemination analysis.  
First, we used an intravenous xenograft to better serve as an orthotopic model 
for MCL engraftment (Klanova, Soukup et al. 2014). Cells were injected into the tail 
vein, with host bone marrow and spleen tissues analyzed after 8 weeks for tumor cell 
engraftment. This methodology served to test the ability of MCL cells to engraft and 
grow in a foreign microenvironment spontaneously. We then investigated on the effects 
a constant pool of tumor cells entering the circulation would have in MCL 
dissemination. We employed a second subcutaneous xenograft model, where MCL 
cells are injected into the skin fold of host mice. This enabled a formation of a primary 
tumor that is palpable cells to be formed, thus providing for a pool of cells that 
constantly disseminate into the host’s system (Molinsky, Klanova et al. 2013).  
18F-FDG have previously been used as a method of monitoring tumor 
dissemination in patients  (Seam, Juweid et al. 2007). We used 18F-FDG to detect 
infiltrated tumor cells as tumor/neoplastic cells absorb more glucose than normal cells 
(Levine and Puzio-Kuter 2010). Of note, 18F-FDG has been reported to be highly 
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absorbed in inflamed tissue as well (Bakheet, Powe et al. 2000). However, the nature 
of our data suggests that 18F-FDG would be an ideal tracking method, as infiltrating 
MCL cells would absorb more glucose and also cause a local inflammatory response, 
thus intensifying on signal recorded. FACS analysis of targets with high glucose 
absorption should be performed to further improve resolution of tumor cell infiltration. 
Interestingly, we found that SP53 PAX5– xenografts to have higher tumor 
dissemination than control xenografts (Figure 32), higher amount of radioactive 18F-
FDG uptake found in the thymus, spleen, bone marrow and lymphnodes of mice. We 
also noticed an increase of glucose uptake in GIT organs of PAX5– xenografts 
compared to control. Dissemination of MCL to components of the gastrointestinal 
system occurs in MCL and we noticed that MCL patients with GIT-involvement all 
express significantly low PAX5 transcript as well (Figure 33). This increase in 
dissemination correlates with our observation that PAX5– MCL cells have a higher rate 
of motility in vitro (Figure 30). Increased motility and adhesion to the microenvironment 
have been implicated in increased lymphoma dissemination (Pals, de Gorter et al. 
2007) with an upregulation of the p38MAPK signaling pathway (Figure 39) reported to 
play a significant role in tumorigenic B cell motility (Bendall, Baraz et al. 2005). 
Collectively, our data points to loss of PAX5 as an important event in MCL 
dissemination, and may be critical for increased engraftment to a foreign 
microenvironment. 
PAX5 Expression Predicts MCL Aggressiveness 
When we analyzed for patient survival from a preexisting database (Leukemia-
Lymphoma Molecular Profiling Project) as previously reported (Rosenwald, Wright et 
al. 2003), we could not find a significant correlation between PAX5 expression and 
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overall survival. This discrepancy could be explained due to methodology of generating 
data; the preexisting database used lymph node biopsies form patients, which may 
contain non-B cells and supporting stromal cells. On the other hand, our data reported 
is based on purified CD19+ B cells. There is still possibility that B cells we collected 
contained normal B cells; however, all MCL patient samples analyzed were classified 
as stage IV with involvement of extranodal sites, indicating minimum amounts of 
normal B cells in these samples. This is an important distinction between our data set 
and what has been previously reported, as we only analyzed PAX5 levels in B cells. 
Alternatively, further analyses of our sample sets for known MCL prognostic markers 
such asKi-67, cyclin D1 (Ives Aguilera, Bijwaard et al. 1998) and SOX11 (Mozos, Royo 
et al. 2009) should be performed to better test the robustness of PAX5 expression as a 
prognostic marker. 
Through analysis of our clinical data set, we discovered that PAX5 levels were 
underexpressed in blastoid MCL. PAX5 levels could be used to predict the prognosis of 
advanced MCL patients, which correlated with a poorer overall survival (Figure 37). 
When comparing to overall survival of blastoid MCL patients, a similar trend is 
observed. Increase of blastoid MCL associated pathway signaling pathway members 
(Rudelius, Pittaluga et al. 2006) as well as compound resistance (such as to 
bortezomib) suggests that PAX5– cells display a more aggressive and clinically 
advanced phenotype compared to control cells. Indeed, it would be interesting to 
determine if loss of PAX5 expression can force an indolent form of MCL to develop into 
a more aggressive blastoid phenotype (Pott, Schrader et al. 2005).     
Our HTS results further clarified the role PAX5 have in drug resistance. PAX5– 
MCL cells are more drug resistant than controls (Figure 44). We noticed a global 
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increase in compound resistance in PAX5– MCL (Figure 49), with compounds targeting 
the canonical MCL signaling pathways to be less efficacious over two replicates 
(Custom Clinical Library) in Jeko PAX5– cells and similarly SP53 PAX5–cells (Figure 
54). Interestingly, there were fewer drugs that inhibited TP53 deletional mutant Jeko 
cells than TP53 wild type SP53 cells, suggesting TP53 mutational status could impact 
drug resistance in MCL. Similarly, Jeko, which is classified as a blastoid variant cell 
line, also exhibit lower amounts of PAX5, enforcing our observation that loss of PAX5 
expression leads to an increase in compound cytotoxic resistance. This overall gain of 
a more aggressive MCL phenotype upon PAX5 loss could be due to PAX5’s role as in 
regulating a large gene repertoire.  
PAX5, MCL and the Novel Frontier 
 MCL patient blood and bone marrow samples displayed significantly lower 
levels of PAX5 transcripts, with the blastoid phenotype particularly low. PAX5– cells had 
increased proliferation, tumorigenic and drug resistant properties, while displaying 
greater motility as well as adhesion to the bone marrow microenvironment in vitro and 
in vivo (Figure 58). The downregulation of PAX5 is seen to occur at a differential level 
(Figure 1), prompting a query on its role in lymhphomagenesis. Since we observed that 
PAX5 expression decreased in cells from disseminated tissue compared to parental 
cell tumors, this hints for PAX5 repression to be an epigenetic event for expression 
regulation (Palmisano, Crume et al. 2003). Analysis of patient genomic DNA for 
methylation sites within the PAX5 promoter would better illustrate our point in PAX5 
expression control in MCL progression, and to determine if loss of PAX5 in MCL is part 
of a stepwise tumorigenic machinery to become a more aggressive phenotype.  
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  Our HTS brought about great avenue for future works. There were a myriad of 
possible ways to analyze and interpret the data; each would bring about a different 
study on the biology and physiology of mantle cell lymphoma. By generating MCL cells 
with differential PAX5 expression, we hope to compare control and PAX5– cells in a 
high throughput manner. The HTS revealed compounds that can potentially target both 
classical MCL variants and the more drug resistant PAX5– cells, thus possibly paving a 
way for efficacious MCL drug discovery (data not shown). Remarkably, we find that 
our PAX5– cells were more resistant to bortezomib treatment in vitro, and analysis of 
our HTS found HSP90 inhibition to be effective in killing PAX5– and normal MCL cells. 
Previous studies have reported on the use of HSP90 inhibitors to target MCL 
(Georgakis, Li et al. 2006) though single compound use yielded only moderate clinical 
activity (Kirschbaum, Frankel et al. 2011, Parekh, Weniger et al. 2011). The possible 
identification of compounds that could be used in a synergistic concerted manner with 
current therapeutic regimens could lead to discovery of a more efficacious treatment 
plan of MCL patients.  
 Alternatively, we have uncovered compounds that specifically target only PAX5– 
cells; compounds (data not shown) that ultimately are efficient in inhibiting PAX5– 
cells. Though not therapeutically viable, identification of such compounds can further 
shed light to the biological and molecular nature of PAX5– MCL cells. Since we also 
report that Raji and Reh, two non-MCL B cell cell lines, have increased proliferation 
upon PAX5 loss, it could be extrapolated that PAX5 serves a tumor suppressor in B cell 
tumors. Thus, PAX5– B cell lymphomas might serve as a functional drug resistant 
preclinical model for other B cell cancers.  
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